



**Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after stroke: an observational study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003105
Article Type:	Research
Date Submitted by the Author:	23-Apr-2013
Complete List of Authors:	Dong, Yanhong; National University Health System, Pharmacology Slavin, Melissa; The University of New South Wales Chan, Bernard; National University Health System, Medicine Venketasubramanian, Narayanaswamy; National University Health System, Memory Aging and Cognition Centre, Department of Pharmacology; National University of Singapore, Division of Neurology, University Medicine Cluster Sharma, Vijay; National University Health System, Medicine Crawford, John; The University of New South Wales Collinson, Simon; National University of Singapore, Psychology Sachdev, Perminder; University of New South Wales, School of Psychiatry chen, christopher; National University Health System, Pharmacology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Stroke < NEUROLOGY, GERIATRIC MEDICINE, REHABILITATION MEDICINE

SCHOLARONE™  
Manuscripts

Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after stroke: an observational study

YanHong Dong, MAppSci,<sup>1,2,3</sup> Melissa Jane Slavin, PhD,<sup>3,4</sup> Bernard Poon-Lap Chan, MD,<sup>5</sup> Narayanaswamy Venketasubramanian, MD,<sup>1,5,6</sup> Vijay Kumar Sharma, MD,<sup>5</sup> John D Crawford, PhD,<sup>3</sup> Simon Lowes Collinson, PhD,<sup>7</sup> Perminder Sachdev, MD, PhD,<sup>3</sup> Christopher Li-Hsian Chen, MD.<sup>1,2</sup>

<sup>1</sup>Memory Aging and Cognition Centre, Department of Pharmacology, National University Health System, Singapore

<sup>2</sup>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>3</sup>Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>4</sup>Dementia Collaborative Research Centre – Assessment and Better Care, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>5</sup>Department of Medicine, National University Health System, Singapore

<sup>6</sup>Neuroscience Clinic, Raffles Hospital, Singapore

<sup>7</sup>Department of Psychology, National University of Singapore, Singapore

#### **CORRESPONDING AUTHOR**

Dr C L-H Chen

Department of Pharmacology

National University Health System

1  
2  
3 Clinical Research Centre, MD11, Level 5, #05-9  
4

5  
6 10 Medical Drive  
7

8  
9 Singapore 117597  
10

11  
12 Phone: +65 65165885  
13

14  
15 Fax: +65 68724101  
16

17  
18 Email: [phccclh@nus.edu.sg](mailto:phccclh@nus.edu.sg)  
19

20  
21 Number of words in abstract: 254 words  
22

23  
24 Number of words in manuscripts: 1981 words  
25

26  
27 Tables: 3  
28

29  
30 Figures: 0  
31

32  
33 Short title: Neurocognitive status predicts functional outcome after stroke  
34

35  
36 Key Words: Stroke, Predictive value of tests, Cognition, NIHSS, Functional outcome  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** To investigate the prognostic value of the neurocognitive status measured by screening instruments, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), obtained at the subacute stroke phase or the baseline ( $\leq 2$  weeks), for functional outcome 3–6 months later.

**Design:** Prospective observational study.

**Setting:** Tertiary stroke neurology service.

**Participants:** 400 patients with a recent ischemic stroke or transient ischemic attack (TIA) received NIHSS, MoCA and MMSE at baseline and were followed up at 3–6 months later.

**Primary outcome measures:** At 3–6 months following index event, functional outcome was measured by the modified Rankin Scale (mRS) scores.

**Results:** Baseline NIHSS, MMSE and MoCA scores individually predicted mRS scores at 3–6 months, with NIHSS being the strongest predictor (NIHSS:  $R^2$ change=0.043,  $p<0.001$ ).

Moreover, baseline MMSE scores had a small but statistically significant incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months, while baseline MoCA scores did not [MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ].

However, in patients with more severe stroke at baseline (defined as NIHSS $>2$ ), both baseline MoCA and MMSE had significant and moderately large incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months [MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  $p=0.021$ ].

**Conclusion:** Cognitive screening at the subacute stroke phase can predict functional outcome independently and improve the predictive value of stroke severity scores for functional outcome 3–6 months later, particularly in patients with more severe stroke.

## ARTICLE SUMMARY

### Article focus

- The prognostic value of neurocognitive status measured by brief screening instruments, the MoCA and the MMSE, individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), at subacute stroke phase for functional outcomes at 3–6 months is unknown.
- We examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS for functional outcome 3–6 months after stroke.
- We also explored the predictive ability of these measures in patients with differing stroke severity.

### Key messages

- Cognitive screening at the subacute stroke phase can predict functional outcome independently. Neurocognitive status measured by baseline MMSE scores adds a small incremental prediction to baseline stroke severity scores for functional outcomes at 3–6 months in stroke patients.
- Unexpectedly, in patients with more severe stroke defined by baseline NIHSS score  $>2$ , neurocognitive status measured by both baseline MMSE and MoCA improve the predictive value of stroke severity scores for functional outcome 3–6 months later.

### Strength and limitations of this study

- The main strength of this study is that we examined the prognostic value of neurocognitive status (MoCA and MMSE) and stroke severity (NIHSS) at subacute stroke phase systematically as a singular measure and in combination for mRS scores

1  
2  
3 3–6 month later in a large sample of stroke patients and in patients with differing  
4  
5 stroke severity.  
6  
7

- 8 • An additional strength is the choice of 3–6 month follow-up because patients were more  
9 likely to resume their daily activities and usual roles within this time frame. Hence, the  
10 findings established in this study can guide early intervention from baseline to 3-6 months  
11 after stroke.  
12  
13
- 14 • The limitation of this study is that we did not systematically examine rehabilitation  
15 services provided for patients from subacute stroke phase to 3-6 months follow-up.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

It is important for early intervention and focused management to have instruments available during the subacute stroke phase for predicting functional outcome 3–6 months later.

Cognitive performance measured by the Montreal Cognitive Assessment (MoCA) and the Mini-mental State Examination (MMSE) administered at the subacute stroke phase predicted patients' functional outcomes at inpatient discharge.[1, 2] Furthermore, patients' post-stroke cognitive functioning measured by a brief neuropsychological battery 2–3 weeks following stroke predicted their functional outcomes 13 months later.[3] No study yet has investigated the utility of patients' neurocognitive status at the subacute stroke phase for predicting functional outcome at 3–6 months. A widely used stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), administered at the subacute stroke phase is predictive of patients' functional outcomes 3–6 months later,[4] but has limited representation of cognitive function.[5] Hence, whether the NIHSS and neurocognitive status at baseline are independently predictive or have additive predictive value for functional outcomes at 3–6 months is unknown.

We therefore examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS at the subacute stroke phase for functional outcome 3–6 months later. In addition, we explored the predictive ability of these measures in patients with differing stroke severity.

## METHODS

### Subjects

The methodology of this study has been described previously.[6] Briefly, we recruited 400 consecutive patients ( $\geq 21$  years old) with a recent ischemic stroke or transient ischemic attack

1  
2  
3 (TIA) ( $\leq 14$  days) during their inpatient admission (subacute stroke phase or baseline) at the  
4 National University Health System in Singapore. Patients were excluded if they had a major  
5 physical disability or an active psychiatric disorder that would impede cognitive testing.  
6  
7  
8

### 9 10 **Standard protocol approvals and patient consent**

11 This study was approved by the National Healthcare Group Domain-Specific Review Board  
12 (DSRB), and was conducted in conformity with the Declaration of Helsinki. Written  
13 informed consent was obtained from all participants and/or legally acceptable representatives.  
14  
15  
16  
17

### 18 19 **Procedures**

20 Patients were assessed using the NIHSS, modified Rankin Scale (mRS) (premorbid and  
21 baseline functioning), MMSE[7] and MoCA[8] at baseline. In addition, their mRS scores  
22 were collected at 3–6 months later. The NIHSS and mRS were administered by certified  
23 research personnel blinded to patients' neurocognitive status at baseline and 3-6 months  
24 follow-up. Similarly, the cognitive screening tests were administered by trained research  
25 psychologists blinded to patients' NIHSS and mRS scores. The patients' functional outcome  
26 was defined by the continuous scores of mRS.  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 37 **Statistical analyses**

38 Hierarchical regression analyses were conducted to examine the incremental contribution of  
39 baseline MMSE and MoCA compared with the baseline NIHSS in predicting functional  
40 outcomes defined by mRS scores at 3–6 months after stroke. In the initial analysis, the  
41 clinically-relevant or significant covariates (i.e., age, sex, years of education, number of  
42 cardiovascular risk factors, premorbid and baseline mRS) were entered in the first block. The  
43 cognitive screening variables (MMSE or MoCA) at baseline were entered in the second block  
44 and the NIHSS scores at baseline were entered in the third block (Model A1 and B1 for  
45 MMSE and MoCA, respectively). Subsequently, the order of entry was altered, with baseline  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 NIHSS scores entered in the second block and either baseline MMSE or MoCA entered at the  
4  
5 third block (Model A2 and B2 for MMSE and MoCA, respectively). In order to explore  
6  
7 predictive value in patients with differing stroke severity, we dichotomized the baseline  
8  
9 NIHSS scores using a median split and repeated these analyses.  
10

11 All statistical analyses were performed with IBM SPSS Statistics Version 20.0 for  
12  
13 Windows.  
14

## 15 16 17 18 **RESULTS**

### 19 **Subject characteristics**

20  
21 The recruited patients were mostly Chinese (70.3%) and male (69.8%), with a mean age of  
22  
23 59.8 (11.6) years and a mean of 7.7 (4.3) years of formal education. Most patients (79.8%)  
24  
25 had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median  
26  
27 premorbid mRS =0). The median interval between the stroke or TIA event and assessment  
28  
29 was 2 days (range: 0–14).  
30  
31  
32  
33

34 At 3–6 months following the index event, patients who were lost to follow-up ( $n=12$ )  
35  
36 were younger and their clinical condition was stabilized faster than those who completed the  
37  
38 follow-up (age:  $52.8\pm 12.9$  vs  $60.0\pm 11.5$ ,  $p=0.03$ ; interval days:  $2.91\pm 2.31$  vs  $2.08\pm 0.90$ ,  
39  
40  $p=0.01$ ). 136 (35.1%) of patients had poor functional outcomes defined by mRS score  $>2$  on  
41  
42 follow-up. The population characteristics can be found in Table 1.  
43  
44

### 45 **The Predictive Ability of the MoCA, MMSE and NIHSS**

46  
47 Using hierarchical regression analyses and controlling for baseline characteristics, the MMSE,  
48  
49 MoCA and NIHSS—as singular measures—predicted mRS scores at 3–6 months after stroke  
50  
51 ( $R^2$  changes of 0.012, 0.007 and 0.043, with  $p$ -values 0.004, 0.029 and  $<0.001$ , respectively;  
52  
53 Table 2). Baseline MMSE scores added a small but statistically significant prediction of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 functional outcomes in addition to baseline NIHSS scores, while baseline MoCA scores did  
4  
5 not (MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ).  
6

7  
8 Using a median split of baseline NIHSS scores at 2, patients with NIHSS scores  $\leq 2$   
9  
10 (median =1, range 0–2) were defined as having less severe stroke and those with NIHSS  
11  
12 score  $>2$  (median = 5, range 3–18) were defined as having more severe stroke. As shown in  
13  
14 Table 3, in patients with NIHSS score  $>2$ , both baseline MMSE and MoCA had a significant  
15  
16 and considerable incremental prediction for functional outcomes at 3-6 months in addition to  
17  
18 baseline NIHSS scores (MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  
19  
20  $p=0.021$ ), while neither baseline neurocognitive measure nor baseline NIHSS showed an  
21  
22 incremental prediction for functional outcome in patients with less severe stroke (NIHSS  
23  
24 score  $\leq 2$ ).  
25  
26

## 27 28 29 **DISCUSSION**

30  
31 Cognitive screening at the subacute stroke phase can predict functional outcome at early  
32  
33 convalescent stroke phase independently. Baseline MMSE scores add a small incremental  
34  
35 prediction to baseline stroke severity scores for functional outcomes at 3-6 months in stroke  
36  
37 patients. Unexpectedly, in patients with more severe stroke defined by baseline NIHSS  
38  
39 score  $>2$ , both baseline MMSE and MoCA improve the predictive value of stroke severity  
40  
41 scores for functional outcome 3–6 months later.  
42  
43  
44

45  
46 The contributions of our study are three-fold. First, our finding that neurocognitive  
47  
48 status at the subacute stroke phase predicts functional outcome at 3–6 months is novel and  
49  
50 consistent with previous studies in inpatient rehabilitation [1, 2] and at 13 months after  
51  
52 stroke.[3] Second, MMSE scores at baseline add a small incremental prediction to baseline  
53  
54 stroke severity scores for functional outcomes 3-6 months later. Third, both baseline MMSE  
55  
56

1  
2  
3 and MoCA showed a considerable incremental effect to the baseline NIHSS scores in  
4  
5 predicting functional outcomes in patients with more severe stroke (NIHSS>2) while neither  
6  
7 neurocognitive measure nor stroke severity score at baseline was predictive for functional  
8  
9 outcome in patients with less severe stroke (NIHSS score  $\leq 2$ ). This may be explained by the  
10  
11 higher recovery potential of patients with more neurological deficits compared to patients  
12  
13 with less severe deficits.  
14

15  
16 There are several strengths of our study. First, we examined the prognostic value of  
17  
18 NIHSS and cognitive status by systematically assessing baseline values individually and in  
19  
20 combination in predicting patients' mRS scores 3–6 month after stroke. Although previous  
21  
22 studies that investigated the predictive power of cognition included baseline NIHSS as a  
23  
24 control variable (along with other baseline characteristics), they did not explore the role of  
25  
26 baseline NIHSS as a predictor itself. [1–3] Second, we chose the 3–6 month follow-up period  
27  
28 because prognosis of functional recovery can be made reliably within 12 weeks after  
29  
30 stroke,[9] and patients were more likely to resume their daily activities and usual roles within  
31  
32 this time frame. Therefore, the findings established in this study can guide early intervention  
33  
34 from baseline to 3-6 months after stroke. Third, we examined the predictive ability of  
35  
36 neurocognitive status and stroke severity measures at baseline for functional outcome at 3-6  
37  
38 months in patients with differing stroke severity.  
39  
40  
41  
42

43 There are several limitations of this study. Our results may not be generalizable as the  
44  
45 majority of patients had less severe stroke, nevertheless, a third had poor functional outcomes  
46  
47 3–6 months after stroke so better prognostic tools are required. We employed cognitive  
48  
49 screening tests at baseline rather than formal neuropsychological assessments, for their  
50  
51 brevity and utility by non-specialist personnel. We did not examine rehabilitation services  
52  
53 systematically as this study was designed to investigate cognitive outcomes after stroke.  
54  
55  
56

1  
2  
3 However, all patients received standard rehabilitation according to the institutional pathway.  
4  
5 In addition, the mRS has been criticized for its lack of specificity,[5] however, it is a  
6  
7 summary of outcomes in functioning and has been widely used in clinical trials as a primary  
8  
9 efficacy measure.  
10

11  
12 In conclusion, neurocognitive status at the subacute stroke phase is independently  
13  
14 predictive of functioning at early convalescent stroke phase. Baseline MMSE scores can add  
15  
16 incremental prediction to baseline stroke severity score for functional outcome 3-6 months  
17  
18 later. Moreover, in patients with more recovery potential, both baseline MMSE and MoCA  
19  
20 can improve baseline stroke severity score in predicting functional outcomes 3–6 months  
21  
22 later. We have previously shown that these screening tests administered at the subacute stroke  
23  
24 phase could also predict cognitive outcomes 3–6 months later.[6] Therefore, the predictive  
25  
26 value and brevity of the MMSE and MoCA warrants their routine use in the subacute stroke  
27  
28 phase in clinical service and early acute stroke trials. Future studies may establish a modified  
29  
30 scale combining the NIHSS and items from the MMSE and MoCA to improve the predictive  
31  
32 ability for functional outcome.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Population characteristics according to the functional outcome

Characteristics N (%)	mRS 0–2		mRS >2		Univariate Analysis
	<i>(n = 252)</i>		<i>(n = 136)</i>		<i>P</i>
Age, mean (SD)	57.9	(10.8)	63.8	(11.8)	<0.001
Gender, female*	68	(27.0%)	52	(38.2%)	0.02
Education, <i>y</i> (mean, SD)	9.8	(4.3)	6.3	(3.7)	<0.001
Ethnicity					0.09
<i>Chinese</i>	188	(74.6%)	87	(64.0%)	
<i>Malay</i>	40	(15.9%)	36	(26.5%)	
<i>Indian</i>	22	(8.7%)	12	(8.8%)	
<i>Others</i>	2	(0.8%)	1	(0.7%)	
Stroke classification					0.001
<i>SAO</i>	114	(45.2%)	60	(44.1%)	
<i>LAA</i>	29	(11.5%)	30	(22.1%)	

Characteristics N (%)	mRS 0–2		mRS >2		Univariate Analysis
		(n = 252)		(n = 136)	P
<i>CE</i>	31	(12.3%)	25	(18.4%)	
<i>UND</i>	11	(4.4%)	7	(5.1%)	
<i>OC</i>	1	(0.4%)	1	(0.7%)	
<i>TIA</i>	66	(26.2%)	13	(9.6%)	
NIHSS (median)*	1		4		<0.001
Premorbid mRS (median)	0		0		<0.001
Baseline mRS (median)*	1		3		<0.001
Mean interval between stroke/TIA and assessment	2.4	(2.0)	3.8	(2.5)	<0.001
Cognitive screening tests					
<i>MMSE (mean, SD)</i>	25.7	(3.3)	22.6	(4.3)	<0.001
<i>MoCA (mean, SD)</i>	22.0	(4.8)	18.1	(5.5)	<0.001
Number of cardiovascular risk factors (median)	2		3		<0.001

Characteristics N (%)	mRS 0–2 (n = 252)		mRS >2 (n = 136)		Univariate Analysis <i>P</i>
Recurrent vascular events (no., %)	10	(4.0%)	8	(6.0%)	0.37

\**P* < 0.050 for logistic regression for binary outcome of mRS scores of 0–1 and ≥ 2.

**mRS** = modified Rankin scale; **SD** = Standard Deviations; **SAO** = small artery occlusion; **LAA** = large artery atherosclerosis; **CE** = cardioembolism; **UND** = undetermined etiology; **OC** = other determined etiology; **TIA** = transient ischemic attack; **NIHSS** = National Institute of Health Stroke Score; **MMSE** = Mini-Mental State Examination; **MoCA** = Montreal Cognitive Assessment.

Table 2. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS scores

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	54.10	<0.001
A1	2	Baseline MMSE	−0.1 (0.031)	0.47	0.012	8.48	0.004
	3	Baseline NIHSS	0.3 (<0.001)	0.51	0.038	29.00	<0.001
A2	2	Baseline NIHSS	0.3 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MMSE	−0.1 (0.031)	0.51	0.006	4.71	0.031
B1	2	Baseline MoCA	−0.08 (0.083)	0.47	0.007	4.80	0.029
	3	Baseline NIHSS	0.31 (<0.001)	0.51	0.040	31.10	<0.001
B2	2	Baseline NIHSS	0.31 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MoCA	−0.08 (0.083)	0.51	0.004	3.02	0.083

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.



Table 3. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS for subsample of patients with NIHSS scores >2 at baseline

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	21.68	<0.001
A1	2	Baseline MMSE	-0.18 (0.010)	0.49	0.036	10.94	0.001
	3	Baseline NIHSS	0.22 (0.001)	0.53	0.034	11.07	0.001
A2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MMSE	-0.18 (0.010)	0.53	0.021	6.83	0.010
B1	2	Baseline MoCA	-0.16 (0.021)	0.49	0.029	8.51	0.004
	3	Baseline NIHSS	0.22 (0.001)	0.52	0.040	12.07	0.001
B2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MoCA	-0.16 (0.021)	0.52	0.017	5.42	0.021

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

1  
2  
3 **Acknowledgments:** The authors thank all participants for their involvement. They also thank  
4  
5 the research team from NUHS Memory Aging and Cognition Centre for data collection and  
6  
7 the NUHS Medical Publications Support Unit for its editorial support.  
8

9  
10 **Contributors:** Y. Dong drafted the original manuscript. Statistical analysis was conducted by  
11  
12 Ms. Y Dong with the guidance from Dr. J Crawford. All authors contributed to one of: study  
13  
14 design, conceptualization, analysis, interpretation of the data, drafting or revision of the  
15  
16 manuscript for intellectual content.  
17

18  
19 **Funding:** This work was supported by a Center Grant from the National Medical Research  
20  
21 Council (NMRC/CG/NUHS/2010). Y. Dong has received research support by a NMRC  
22  
23 fellowship training award.  
24

25  
26 **Competing interests:** None.  
27

28  
29 **Patient consent:** Obtained.  
30

31  
32 **Ethics approval:** National Healthcare Group Domain-Specific Ethics Review Board.  
33

34  
35 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
36

37  
38 **Data sharing statement:** No additional data are available.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Toglia J, Fitzgerald KA, O'Dell MW, *et al.* The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. *Arch Phys Med Rehabil* 2011;**92**:792–8.
- 2 Zwecker M, Levenkrohn S, Fleisig Y, *et al.* Mini-Mental State Examination, Cognitive FIM Instrument, and the Loewenstein Occupational Therapy Cognitive Assessment: relation to functional outcome of stroke patients. *Arch Phys Med Rehabil* 2002;**83**:342–5.
- 3 Wagle J, Farner L, Flekkøy K, *et al.* Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. *Dement Geriatr Cogn Disord* 2011;**31**:379–7.
- 4 Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. *Stroke* 2012;**43**:560–2.
- 5 Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;**5**:603–12.
- 6 Dong Y, Venketasubramanian N, Chan BP, *et al.* Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3–6 months after stroke. *J Neurol Neurosurg Psychiatry* 2012;**83**:580–5.
- 7 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;**12**:189–98.
- 8 Nasreddine ZS, Phillips NA, Bédirian V, *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;**53**:695–9.

1  
2  
3 9 Jørgensen HS, Nakayama H, Raaschou HO, *et al.* Outcome and time course of recovery  
4 in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. *Arch Phys*  
5  
6 *Med Rehabil* 1995;**76**:406-12.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after stroke: an observational study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003105.R1
Article Type:	Research
Date Submitted by the Author:	15-Jul-2013
Complete List of Authors:	Dong, Yanhong; National University Health System, Pharmacology Slavin, Melissa; The University of New South Wales Chan, Bernard; National University Health System, Medicine Venketasubramanian, Narayanaswamy; National University Health System, Memory Aging and Cognition Centre, Department of Pharmacology; National University of Singapore, Division of Neurology, University Medicine Cluster Sharma, Vijay; National University Health System, Medicine Crawford, John; The University of New South Wales Collinson, Simon; National University of Singapore, Psychology Sachdev, Perminder; University of New South Wales, School of Psychiatry chen, christopher; National University Health System, Pharmacology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Stroke < NEUROLOGY, GERIATRIC MEDICINE, REHABILITATION MEDICINE

SCHOLARONE™  
Manuscripts

Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after stroke: an observational study

YanHong Dong, MAppSci,<sup>1,2,3</sup> Melissa Jane Slavin, PhD,<sup>3,4</sup> Bernard Poon-Lap Chan, MD,<sup>5</sup> Narayanaswamy Venketasubramanian, MD,<sup>1,5,6</sup> Vijay Kumar Sharma, MD,<sup>5</sup> John D Crawford, PhD,<sup>3</sup> Simon Lowes Collinson, PhD,<sup>7</sup> Perminder Sachdev, MD, PhD,<sup>3</sup> Christopher Li-Hsian Chen, MD.<sup>1,2</sup>

<sup>1</sup>Memory Aging and Cognition Centre, Department of Pharmacology, National University Health System, Singapore

<sup>2</sup>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>3</sup>Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>4</sup>Dementia Collaborative Research Centre – Assessment and Better Care, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>5</sup>Department of Medicine, National University Health System, Singapore

<sup>6</sup>Neuroscience Clinic, Raffles Hospital, Singapore

<sup>7</sup>Department of Psychology, National University of Singapore, Singapore

#### **CORRESPONDING AUTHOR**

Dr C L-H Chen

Department of Pharmacology

National University Health System

1  
2  
3 Clinical Research Centre, MD11, Level 5, #05-9  
4

5  
6 10 Medical Drive  
7

8  
9 Singapore 117597  
10

11  
12 Phone: +65 65165885  
13

14  
15 Fax: +65 68724101  
16

17  
18 Email: [phccclh@nus.edu.sg](mailto:phccclh@nus.edu.sg)  
19

20  
21 Number of words in abstract: 254 words  
22

23  
24 Number of words in manuscripts: 2283 words  
25

26  
27 Tables: 3  
28

29  
30 Figures: 0  
31

32  
33 Short title: Neurocognitive status predicts functional outcome after stroke  
34

35  
36 Key Words: Stroke, Predictive value of tests, Cognition, NIHSS, Functional outcome  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** To investigate the prognostic value of the neurocognitive status measured by screening instruments, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), obtained at the subacute stroke phase or the baseline ( $\leq 2$  weeks), for functional outcome 3–6 months later.

**Design:** Prospective observational study.

**Setting:** Tertiary stroke neurology service.

**Participants:** 400 patients with a recent ischemic stroke or transient ischemic attack (TIA) received NIHSS, MoCA and MMSE at baseline and were followed up at 3–6 months later.

**Primary outcome measures:** At 3–6 months following index event, functional outcome was measured by the modified Rankin Scale (mRS) scores.

**Results:** Baseline NIHSS, MMSE and MoCA scores individually predicted mRS scores at 3–6 months, with NIHSS being the strongest predictor (NIHSS:  $R^2$ change=0.043,  $p<0.001$ ).

Moreover, baseline MMSE scores had a small but statistically significant incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months, while baseline MoCA scores did not [MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ].

However, in patients with more severe stroke at baseline (defined as NIHSS $>2$ ), both baseline MoCA and MMSE had significant and moderately large incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months [MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  $p=0.021$ ].

**Conclusion:** Cognitive screening at the subacute stroke phase can predict functional outcome independently and improve the predictive value of stroke severity scores for functional outcome 3–6 months later, particularly in patients with more severe stroke.



## ARTICLE SUMMARY

### Article focus

- The prognostic value of neurocognitive status measured by brief screening instruments, the MoCA and the MMSE, individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), at subacute stroke phase for functional outcomes at 3–6 months is unknown.
- We examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS for functional outcome 3–6 months after stroke.
- We also explored the predictive ability of these measures in patients with differing stroke severity.

### Key messages

- Cognitive screening at the subacute stroke phase can predict functional outcome independently. Neurocognitive status measured by baseline MMSE scores adds a small incremental prediction to baseline stroke severity scores for functional outcomes at 3–6 months in stroke patients.
- Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ , neurocognitive status measured by both baseline MMSE and MoCA improve the predictive value of stroke severity scores for functional outcome 3–6 months later. However, the incremental predictive value of the MMSE and MoCA is relatively smaller than the NIHSS.

### Strength and limitations of this study

- The main strength of this study is that we examined the prognostic value of neurocognitive status (MoCA and MMSE) and stroke severity (NIHSS) at subacute

1  
2  
3 stroke phase systematically as a singular measure and in combination for mRS scores  
4  
5 3–6 month later in a large sample of stroke patients and in patients with differing  
6  
7 stroke severity.  
8  
9

- 10 • An additional strength is the choice of 3–6 month follow-up because patients were more  
11 likely to resume their daily activities and usual roles within this time frame. Hence, the  
12 findings established in this study can guide early intervention from baseline to 3-6 months  
13 after stroke.  
14  
15
- 16 • The limitation of this study is that we did not systematically examine rehabilitation  
17 services provided for patients from subacute stroke phase to 3-6 months follow-up.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

It is important for early intervention and focused management to have instruments available during the subacute stroke phase for predicting functional outcome 3–6 months later.

Cognitive performance measured by the Montreal Cognitive Assessment (MoCA) and the Mini-mental State Examination (MMSE) administered at the subacute stroke phase predicted patients' functional outcomes at inpatient discharge (1, 2). Furthermore, patients' post-stroke cognitive functioning measured by a brief neuropsychological battery 2–3 weeks following stroke predicted their functional outcomes 13 months later (3). No study yet has investigated the utility of patients' neurocognitive status at the subacute stroke phase for predicting functional outcome at 3–6 months. A widely used stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), administered at the subacute stroke phase is predictive of patients' functional outcomes 3–6 months later (4), but has limited representation of cognitive function (5). Hence, whether the NIHSS and neurocognitive status at baseline are independently predictive or have additive predictive value for functional outcomes at 3–6 months is unknown.

We therefore examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS at the subacute stroke phase for functional outcome 3–6 months later. In addition, we explored the predictive ability of these measures in patients with differing stroke severity.

## METHODS

### Subjects

The methodology of this study has been described previously (6). [6] Briefly, we recruited 400 consecutive patients ( $\geq 21$  years old) with a recent ischemic stroke or transient ischemic

1  
2  
3 attack (TIA) ( $\leq 14$  days) during their inpatient admission (subacute stroke phase or baseline)  
4  
5 at the National University Health System in Singapore. Patients were excluded if they had a  
6  
7 major physical disability or an active psychiatric disorder that would impede cognitive testing.  
8

### 9 10 **Standard protocol approvals and patient consent**

11 This study was approved by the National Healthcare Group Domain-Specific Review Board  
12  
13 (DSRB), and was conducted in conformity with the Declaration of Helsinki. Written  
14  
15 informed consent was obtained from all participants and/or legally acceptable representatives.  
16  
17

### 18 19 **Procedures**

20 Patients were assessed using the NIHSS, modified Rankin Scale (mRS) (premorbid and  
21  
22 baseline functioning), MMSE (7) and MoCA (8) at baseline. In addition, their mRS scores  
23  
24 were collected at 3–6 months later. The NIHSS and mRS were administered by certified  
25  
26 research personnel blinded to patients' neurocognitive status at baseline and 3-6 months  
27  
28 follow-up. Similarly, the cognitive screening tests were administered by trained research  
29  
30 psychologists blinded to patients' NIHSS and mRS scores. The patients' functional outcome  
31  
32 was defined by the continuous scores of mRS.  
33  
34

### 35 36 37 **Statistical analyses**

38 Between-group differences were examined using independent-sample *t* test for quantitative  
39  
40 variables and Pearson's  $\chi^2$  test for categorical variables. Hierarchical regression analyses  
41  
42 were conducted to examine the incremental contribution of baseline MMSE and MoCA  
43  
44 compared with the baseline NIHSS in predicting functional outcomes defined by mRS scores  
45  
46 at 3–6 months after stroke. In the initial analysis, the clinically-relevant or significant  
47  
48 covariates (i.e., age, sex, years of education, number of cardiovascular risk factors, premorbid  
49  
50 and baseline mRS) were entered in the first block. The cognitive screening variables (MMSE  
51  
52 or MoCA) at baseline were entered in the second block and the NIHSS scores at baseline  
53  
54  
55

1  
2  
3 were entered in the third block (Model A1 and B1 for MMSE and MoCA, respectively).  
4  
5 Subsequently, the order of entry was altered, with baseline NIHSS scores entered in the  
6  
7 second block and either baseline MMSE or MoCA entered at the third block (Model A2 and  
8  
9 B2 for MMSE and MoCA, respectively). In order to explore predictive value in patients with  
10  
11 differing stroke severity, we dichotomized the baseline NIHSS scores using a median split  
12  
13 and repeated these analyses.  
14

15  
16 All statistical analyses were performed with IBM SPSS Statistics Version 20.0 for  
17  
18 Windows.  
19

## 20 21 22 23 **RESULTS**

### 24 25 **Subject characteristics**

26  
27 The recruited patients were mostly Chinese (70.3%) and male (69.8%), with a mean age of  
28  
29 59.8 (11.6) years and a mean of 7.7 (4.3) years of formal education. Most patients (79.8%)  
30  
31 had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median  
32  
33 premorbid mRS =0). The median interval between the stroke or TIA event and assessment  
34  
35 was 2 days (range: 0–14).  
36  
37

38  
39 At 3–6 months following the index event, patients who were lost to follow-up ( $n=12$ )  
40  
41 were younger and their clinical condition was stabilized faster than those who completed the  
42  
43 follow-up (age:  $52.8\pm 12.9$  vs  $60.0\pm 11.5$ ,  $p=0.03$ ; interval days:  $2.91\pm 2.31$  vs  $2.08\pm 0.90$ ,  
44  
45  $p=0.01$ ). We defined favorable functional outcome as mRS score  $\leq 1$  and poor functional  
46  
47 outcome as mRS score  $\geq 2$ . This dichotomized mRS scores for favorable and poor functional  
48  
49 outcome is commonly used and is in keeping with the recommendation from previous  
50  
51 analyses (9). The majority of the patients ( $n=252$ , 64.9%) had good functional outcomes  
52  
53 (mRSscore  $\leq 1$ ) while approximately one third of the patients ( $n=136$ , 35.1%) had poor  
54  
55

1  
2  
3 functional outcomes (mRS score  $\geq 2$ ). Patients with poor functional outcome were  
4  
5 significantly older, women, of Malay ethnicity, less educated, more neurologically impaired  
6  
7 with poorer premorbid and baseline functioning, and assessed later following cerebrovascular  
8  
9 event. They also had more stroke classification of large artery occlusion and cardioembolic  
10  
11 stroke, as well as higher number of cardiovascular risk factors. In addition, patients with  
12  
13 poorer functional outcome had significantly lower scores of the MMSE and the MoCA. The  
14  
15 population characteristics of patients with favorable and poor functional outcomes can be  
16  
17 found in Table 1.  
18  
19

### 20 **The Predictive Ability of the MoCA, MMSE and NIHSS**

21  
22 Using hierarchical regression analyses and controlling for baseline characteristics, the MMSE,  
23  
24 MoCA and NIHSS—as singular measures—predicted mRS scores at 3–6 months after stroke  
25  
26 ( $R^2$  changes of 0.012, 0.007 and 0.043, with  $p$ -values 0.004, 0.029 and  $<0.001$ , respectively;  
27  
28 Table 2). Baseline MMSE scores added a small but statistically significant prediction of  
29  
30 functional outcomes in addition to baseline NIHSS scores, while baseline MoCA scores did  
31  
32 not (MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ).  
33  
34  
35

36 Using a median split of baseline NIHSS scores at 2, patients with NIHSS scores  $\leq 2$   
37  
38 (median =1, range 0–2) were defined as having less severe stroke and those with NIHSS  
39  
40 score  $>2$  (median = 5, range 3–18) were defined as having more severe stroke. As shown in  
41  
42 Table 3, in patients with NIHSS score  $>2$ , both baseline MMSE and MoCA had a significant  
43  
44 and considerable incremental prediction for functional outcomes at 3-6 months in addition to  
45  
46 baseline NIHSS scores (MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  
47  
48  $p=0.021$ ), while neither baseline neurocognitive measure nor baseline NIHSS showed an  
49  
50 incremental prediction for functional outcome in patients with less severe stroke (NIHSS  
51  
52 score  $\leq 2$ ).  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Cognitive screening at the subacute stroke phase can predict functional outcome at early convalescent stroke phase independently. Baseline MMSE scores add a small incremental prediction to baseline stroke severity scores for functional outcomes at 3-6 months in stroke patients. Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ , both baseline MMSE and MoCA improve the predictive value of stroke severity scores for functional outcome 3–6 months later. However, the incremental predictive value of the MMSE and MoCA is relatively smaller than the NIHSS.

The contributions of our study are three-fold. First, our finding that neurocognitive status at the subacute stroke phase predicts functional outcome at 3–6 months is novel and consistent with previous studies in inpatient rehabilitation (1, 2) and at 13 months after stroke (3). Second, MMSE scores at baseline add a small incremental prediction to baseline stroke severity scores for functional outcomes 3-6 months later. Third, both baseline MMSE and MoCA showed a considerable incremental effect to the baseline NIHSS scores in predicting functional outcomes in patients with more severe stroke (NIHSS $>2$ ) while neither neurocognitive measure nor stroke severity score at baseline was predictive for functional outcome in patients with less severe stroke (NIHSS score  $\leq 2$ ). This may be explained by the higher recovery potential of patients with more neurological deficits compared to patients with less severe deficits.

There are several strengths of our study. First, we examined the prognostic value of NIHSS and cognitive status by systematically assessing baseline values individually and in combination in predicting patients' mRS scores 3–6 month after stroke. Although previous studies that investigated the predictive power of cognition included baseline NIHSS as a control variable (along with other baseline characteristics), they did not explore the role of

1  
2  
3 baseline NIHSS as a predictor itself (1-3). Second, we chose the 3–6 month follow-up period  
4  
5 because prognosis of functional recovery can be made reliably within 12 weeks after stroke  
6  
7 (10), and patients were more likely to resume their daily activities and usual roles within this  
8  
9 time frame. Therefore, the findings established in this study can guide early intervention from  
10  
11 baseline to 3-6 months after stroke. Third, we examined the predictive ability of  
12  
13 neurocognitive status and stroke severity measures at baseline for functional outcome at 3-6  
14  
15 months in patients with differing stroke severity.  
16  
17

18  
19 There are several limitations of this study. First, our results may not be generalizable  
20  
21 as the majority of patients had less severe stroke, nevertheless, a third had poor functional  
22  
23 outcomes 3–6 months after stroke so better prognostic tools are required. Second, we  
24  
25 employed cognitive screening tests at baseline rather than formal neuropsychological  
26  
27 assessments, for their brevity and utility by non-specialist personnel. Third, we did not  
28  
29 examine rehabilitation services systematically as this information was not collected .  
30  
31 However, all patients received standard rehabilitation according to the institutional pathway.  
32  
33 Fourth, the mRS has been criticized for its lack of specificity (5), however, it is a summary of  
34  
35 outcomes in functioning and has been widely used in clinical trials as a primary efficacy  
36  
37 measure. Last, we did not consider other predictive scores (e.g., PLAN score (11), iScore (12),  
38  
39 six simple variable (13) and five simple variable scores (14)) for our models primarily due to  
40  
41 the following reasons: 1) None of these scores include a cognitive measure.; 2) PLAN scores  
42  
43 are developed using more severe functional outcome measure, such as mRS scores of 5 to 6  
44  
45 at discharge. Similarly, iScore has been used to estimate poor functional outcome defined by  
46  
47 mRS 3 to 5. ; 3) Six simple variable and five simple variable scores require Glasgow Coma  
48  
49 Scale which we did not collect in this study. Therefore, we are unable to adopt these models  
50  
51 to predict functional outcome in this study. However, in line with our aims, we included  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 significant and clinically relevant predictors as control variables (age, sex, education,  
4  
5 composite of cardiovascular risk factors, premorbid mRS and baseline mRS) in our models.  
6

7  
8 In conclusion, 4.3% of the functional outcome after 3-6 months can be predicted early  
9  
10 after admission by NIHSS, with its many functional and only few cognitive items. Premorbid  
11  
12 and baseline factors alone however, explain almost half of the variance. In addition,  
13  
14 neurocognitive status at the subacute stroke phase is independently predictive of functioning  
15  
16 at early convalescent stroke phase. Baseline MMSE scores can add incremental prediction to  
17  
18 baseline stroke severity score for functional outcome 3-6 months later. Moreover, in patients  
19  
20 with more recovery potential, both baseline MMSE and MoCA can improve baseline stroke  
21  
22 severity score in predicting functional outcomes 3–6 months later. We have previously shown  
23  
24 that these screening tests administered at the subacute stroke phase could also predict  
25  
26 cognitive outcomes 3–6 months later (6). In addition, MoCA administration has been reported  
27  
28 to be applicable to the majority of acute stroke patients (ischemic or hemorrhagic)  
29  
30 (82.5%), and therefore feasible to be used in acute stroke phase (15). Therefore, the predictive  
31  
32 value and brevity of the MMSE and MoCA warrants their routine use in the subacute stroke  
33  
34 phase in clinical service and early acute stroke trials. However, the current instruments  
35  
36 (NIHSS in combination with MMSE or MoCA) could only predict for 51% of the functional  
37  
38 outcome. Therefore, it would be helpful if a better prognostic tool can improve the prediction  
39  
40 for functional outcome to 70%-80%. Future studies may establish a modified scale  
41  
42 combining the NIHSS and items from the MMSE and MoCA to improve the predictive  
43  
44 ability for functional outcome.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Population characteristics according to the functional outcome defined by mRS scores at 3-6 months after stroke

Characteristics N (%)	mRS 0–1		mRS ≥2		Univariate Analysis
	(n = 252)		(n = 136)		P
Age, mean (SD)	57.9	(10.8)	63.8	(11.8)	<0.001
Gender, female	68	(27.0%)	52	(38.2%)	0.02
Education, y (mean, SD)	9.8	(4.3)	6.3	(3.7)	<0.001
Ethnicity					0.039
<i>Chinese</i>	188	(74.6%)	87	(64.0%)	
<i>Malay</i>	40	(15.9%)	36	(26.5%)	
<i>Indian and others</i>	24	(9.5%)	13	(9.6%)	
Stroke classification					<0.001
<i>SAO</i>	114	(45.2%)	60	(44.1%)	
<i>LAA</i>	29	(11.5%)	30	(22.1%)	
<i>CE</i>	31	(12.3%)	25	(18.4%)	

Characteristics N (%)	mRS 0–1		mRS ≥2		Univariate Analysis
	(n = 252)		(n = 136)		P
<i>UND and OC</i>	12	(4.8%)	8	(5.9%)	
<i>TIA</i>	66	(26.2%)	13	(9.6%)	
NIHSS ( mean, SD)	1.46	(1.83)	5.04	(3.68)	<0.001
Premorbid mRS (median )	0.06	(0.29)	0.54	(1.05)	<0.001
Baseline mRS (median )	1.28	(1.20)	3.04	(1.21)	<0.001
Mean interval (days) between stroke/TIA and assessment	2.4	(2.0)	3.8	(2.5)	<0.001
Cognitive screening tests					
<i>MMSE (mean, SD)</i>	25.7	(3.3)	22.6	(4.3)	<0.001
<i>MoCA (mean, SD)</i>	22.0	(4.8)	18.1	(5.5)	<0.001
Number of cardiovascular risk factors (median)	2		3		<0.001
Recurrent vascular events (no., %)	10	(4.0%)	8	(6.0%)	0.37

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Characteristics N (%)	mRS 0–1	mRS ≥2	Univariate Analysis
	<i>(n = 252)</i>	<i>(n = 136)</i>	<i>P</i>

**mRS** = modified Rankin scale; **SD**= Standard Deviations; **SAO** = small artery occlusion; **LAA**= large artery atherosclerosis; **CE** = cardioembolism; **UND** = undetermined etiology; **OC** = other determined etiology; **TIA**= transient ischemic attack; **NIHSS** = National Institute of Health Stroke Score; **MMSE**=Mini-Mental State Examination; **MoCA**=Montreal Cognitive Assessment.

For Peer review only

Table 2. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS scores

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	54.10	<0.001
A1	2	Baseline MMSE	−0.1 (0.031)	0.47	0.012	8.48	0.004
	3	Baseline NIHSS	0.3 (<0.001)	0.51	0.038	29.00	<0.001
A2	2	Baseline NIHSS	0.3 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MMSE	−0.1 (0.031)	0.51	0.006	4.71	0.031
B1	2	Baseline MoCA	−0.08 (0.083)	0.47	0.007	4.80	0.029
	3	Baseline NIHSS	0.31 (<0.001)	0.51	0.040	31.10	<0.001
B2	2	Baseline NIHSS	0.31 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MoCA	−0.08 (0.083)	0.51	0.004	3.02	0.083

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

Table 3. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS for subsample of patients with NIHSS scores >2 at baseline

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	21.68	<0.001
A1	2	Baseline MMSE	−0.18 (0.010)	0.49	0.036	10.94	0.001
	3	Baseline NIHSS	0.22 (0.001)	0.53	0.034	11.07	0.001
A2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MMSE	−0.18 (0.010)	0.53	0.021	6.83	0.010
B1	2	Baseline MoCA	−0.16 (0.021)	0.49	0.029	8.51	0.004
	3	Baseline NIHSS	0.22 (0.001)	0.52	0.040	12.07	0.001
B2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MoCA	−0.16 (0.021)	0.52	0.017	5.42	0.021

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

1  
2  
3 **Acknowledgments:** The authors thank all participants for their involvement. They also thank  
4  
5 the research team from NUHS Memory Aging and Cognition Centre for data collection and  
6  
7 the NUHS Medical Publications Support Unit for its editorial support.  
8

9  
10 **Contributors:** Y. Dong drafted the original manuscript. Statistical analysis was conducted by  
11  
12 Ms. Y Dong with the guidance from Dr. J Crawford. All authors contributed to one of: study  
13  
14 design, conceptualization, analysis, interpretation of the data, drafting or revision of the  
15  
16 manuscript for intellectual content.  
17

18  
19 **Funding:** This work was supported by a Center Grant from the National Medical Research  
20  
21 Council (NMRC/CG/NUHS/2010). Y. Dong has received research support by a NMRC  
22  
23 fellowship training award.  
24

25  
26 **Competing interests:** None.  
27

28  
29 **Patient consent:** Obtained.  
30

31  
32 **Ethics approval:** National Healthcare Group Domain-Specific Ethics Review Board.  
33

34  
35 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
36

37  
38 **Data sharing statement:** No additional data are available.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Toglia J, Fitzgerald KA, O'Dell MW, *et al.* The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. *Arch Phys Med Rehabil* 2011;**92**:792–8.
- 2 Zwecker M, Levenkrohn S, Fleisig Y, *et al.* Mini-Mental State Examination, Cognitive FIM Instrument, and the Loewenstein Occupational Therapy Cognitive Assessment: relation to functional outcome of stroke patients. *Arch Phys Med Rehabil* 2002;**83**:342–5.
- 3 Wagle J, Farner L, Flekkøy K, *et al.* Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. *Dement Geriatr Cogn Disord* 2011;**31**:379–7.
- 4 Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. *Stroke* 2012;**43**:560–2.
- 5 Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;**5**:603–12.
- 6 Dong Y, Venketasubramanian N, Chan BP, *et al.* Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3–6 months after stroke. *J Neurol Neurosurg Psychiatry* 2012;**83**:580–5.
- 7 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;**12**:189–98.
- 8 Nasreddine ZS, Phillips NA, Bédirian V, *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;**53**:695–9.
- 9 Weisscher, N, Vermeulen M, Ross YB, *et al.* What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2? *J Neurol* 2008;**255**:867-874.



- 1  
2  
3 10 Jørgensen HS, Nakayama H, Raaschou HO, *et al.* Outcome and time course of recovery  
4 in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. *Arch Phys*  
5 *Med Rehabil* 1995;**76**:406-12.  
6  
7  
8  
9  
10 11 O'Donnell MJ, Fang J, D'Uva C, *et al.* The PLAN Score: A bedside prediction rule for  
11 death and severe disability following acute ischemic stroke. *Arch Intern Med*  
12 2012;**172**:1548-1556.  
13  
14  
15 12 Saposnik G, Raptis S, Kapral MK, *et al.* The iScore predicts poor functional outcomes  
16 early after hospitalization for an acute ischemic stroke. *Stroke* 2011;**42**:3421-3428.  
17  
18  
19 20 13 Reid JM, Gubitz GJ, Dai D, *et al.* External validation of a six simple variable model of  
21 stroke outcome and verification in hyper-acute stroke. *J Neurol Neurosurg Psychiatry*  
22 2007;**78**:1390-1391.  
23  
24  
25 26 14 Ayis SA, Coker B, Rudd AG, *et al.* Predicting independent survival after stroke: a  
27 European study for the development and validation of a standardised stroke scales and  
28 prediction models of outcome. *J Neurol Neurosurg Psychiatry* 2013;**84**:288-296.  
29  
30  
31 32 15 Pasi M, Salvadori E, Poggesi A, *et al.* Factors predicting the Montreal cognitive  
33 assessment (MoCA) applicability and performances in a stroke unit. *J Neurol*  
34 2013;**260**:1518-1526.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after stroke: an observational study

YanHong Dong, MAppSci,<sup>1,2,3</sup> Melissa Jane Slavin, PhD,<sup>3,4</sup> Bernard Poon-Lap Chan, MD,<sup>5</sup> Narayanaswamy Venketasubramanian, MD,<sup>1,5,6</sup> Vijay Kumar Sharma, MD,<sup>5</sup> John D Crawford, PhD,<sup>3</sup> Simon Lowes Collinson, PhD,<sup>7</sup> Perminder Sachdev, MD, PhD,<sup>3</sup> Christopher Li-Hsian Chen, MD.<sup>1,2</sup>

<sup>1</sup>Memory Aging and Cognition Centre, Department of Pharmacology, National University Health System, Singapore

<sup>2</sup>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>3</sup>Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>4</sup>Dementia Collaborative Research Centre – Assessment and Better Care, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>5</sup>Department of Medicine, National University Health System, Singapore

<sup>6</sup>Neuroscience Clinic, Raffles Hospital, Singapore

<sup>7</sup>Department of Psychology, National University of Singapore, Singapore

#### **CORRESPONDING AUTHOR**

Dr C L-H Chen

Department of Pharmacology

National University Health System

1

1  
2  
3  
4  
5  
6  
7 Clinical Research Centre, MD11, Level 5, #05-9

8  
9 10 Medical Drive

10  
11 Singapore 117597

12  
13  
14 Phone: +65 65165885

15  
16 Fax: +65 68724101

17  
18  
19 Email: [phccclh@nus.edu.sg](mailto:phccclh@nus.edu.sg)

20  
21 Number of words in abstract: 254 words

22  
23  
24 Number of words in manuscripts: ~~2283~~<sup>1981</sup> words

25  
26 Tables: 3

27  
28 Figures: 0

29  
30 Short title: Neurocognitive status predicts functional outcome after stroke

31  
32 Key Words: Stroke, Predictive value of tests, Cognition, NIHSS, Functional outcome

**ABSTRACT**

**Objectives:** To investigate the prognostic value of the neurocognitive status measured by screening instruments, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), obtained at the subacute stroke phase or the baseline ( $\leq 2$  weeks), for functional outcome 3–6 months later.

**Design:** Prospective observational study.

**Setting:** Tertiary stroke neurology service.

**Participants:** 400 patients with a recent ischemic stroke or transient ischemic attack (TIA) received NIHSS, MoCA and MMSE at baseline and were followed up at 3-6 months later.

**Primary outcome measures:** At 3-6 months following index event, functional outcome was measured by the modified Rankin Scale (mRS) scores.

**Results:** Baseline NIHSS, MMSE and MoCA scores individually predicted mRS scores at 3–6 months, with NIHSS being the strongest predictor (NIHSS:  $R^2$ change=0.043,  $p<0.001$ ).

Moreover, baseline MMSE scores had a small but statistically significant incremental predictive value to the baseline NIHSS for mRS scores at 3-6 months, while baseline MoCA scores did not [MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ].

However, in patients with more severe stroke at baseline (defined as NIHSS $>2$ ), both baseline MoCA and MMSE had significant and moderately large incremental predictive value to the baseline NIHSS for mRS scores at 3-6 months [MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  $p=0.021$ ].

**Conclusion:** Cognitive screening at the subacute stroke phase can predict functional outcome independently and improve the predictive value of stroke severity scores for functional outcome 3–6 months later, particularly in patients with more severe stroke.

## ARTICLE SUMMARY

### Article focus

- The prognostic value of neurocognitive status measured by brief screening instruments, the MoCA and the MMSE, individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), at subacute stroke phase for functional outcomes at 3–6 months is unknown.
- We examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS for functional outcome 3–6 months after stroke.
- We also explored the predictive ability of these measures in patients with differing stroke severity.

### Key messages

- Cognitive screening at the subacute stroke phase can predict functional outcome independently. Neurocognitive status measured by baseline MMSE scores adds a small incremental prediction to baseline stroke severity scores for functional outcomes at 3–6 months in stroke patients.
- Unexpectedly Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ , neurocognitive status measured by both baseline MMSE and MoCA improve the predictive value of stroke severity scores for functional outcome 3–6 months later. However, the incremental predictive value of the MMSE and MoCA is relatively smaller than the NIHSS.

### Strength and limitations of this study

- The main strength of this study is that we examined the prognostic value of neurocognitive status (MoCA and MMSE) and stroke severity (NIHSS) at subacute

1  
2  
3  
4  
5  
6  
7 stroke phase systematically as a singular measure and in combination for mRS scores  
8  
9 3–6 month later in a large sample of stroke patients and in patients with differing  
10  
11 stroke severity.

- 12  
13 • An additional strength is the choice of 3–6 month follow-up because patients were more  
14  
15 likely to resume their daily activities and usual roles within this time frame. Hence, the  
16  
17 findings established in this study can guide early intervention from baseline to 3-6 months  
18  
19 after stroke.
- 20  
21 • The limitation of this study is that we did not systematically examine rehabilitation  
22  
23 services provided for patients from subacute stroke phase to 3-6 months follow-up.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

## INTRODUCTION

It is important for early intervention and focused management to have instruments available during the subacute stroke phase for predicting functional outcome 3–6 months later.

Cognitive performance measured by the Montreal Cognitive Assessment (MoCA) and the Mini-mental State Examination (MMSE) administered at the subacute stroke phase predicted patients' functional outcomes at inpatient discharge (1, 2).<sup>[1, 2]</sup> Furthermore, patients' post-stroke cognitive functioning measured by a brief neuropsychological battery 2–3 weeks following stroke predicted their functional outcomes 13 months later (3).<sup>[3]</sup> No study yet has investigated the utility of patients' neurocognitive status at the subacute stroke phase for predicting functional outcome at 3–6 months. A widely used stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), administered at the subacute stroke phase is predictive of patients' functional outcomes 3–6 months later (4).<sup>[4]</sup> but has limited representation of cognitive function (5).<sup>[5]</sup> Hence, whether the NIHSS and neurocognitive status at baseline are independently predictive or have additive predictive value for functional outcomes at 3–6 months is unknown.

We therefore examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS at the subacute stroke phase for functional outcome 3–6 months later. In addition, we explored the predictive ability of these measures in patients with differing stroke severity.

## METHODS

### Subjects

The methodology of this study has been described previously (6).<sup>[6]</sup> Briefly, we recruited 400 consecutive patients ( $\geq 21$  years old) with a recent ischemic stroke or transient ischemic

1  
2  
3  
4  
5  
6  
7 attack (TIA) ( $\leq 14$  days) during their inpatient admission (subacute stroke phase or baseline)  
8  
9 at the National University Health System in Singapore. Patients were excluded if they had a  
10  
11 major physical disability or an active psychiatric disorder that would impede cognitive testing.

### 12 **Standard protocol approvals and patient consent**

14 This study was approved by the National Healthcare Group Domain-Specific Review Board  
15 (DSRB), and was conducted in conformity with the Declaration of Helsinki. Written  
16  
17 informed consent was obtained from all participants and/or legally acceptable representatives.  
18  
19

### 20 **Procedures**

21 Patients were assessed using the NIHSS, modified Rankin Scale (mRS) (premorbid and  
22  
23 baseline functioning), MMSE<sup>(7)</sup> and MoCA<sup>(8)</sup> at baseline. In addition, their mRS scores  
24  
25 were collected at 3–6 months later. The NIHSS and mRS were administered by certified  
26  
27 research personnel blinded to patients' neurocognitive status at baseline and 3-6 months  
28  
29 follow-up. Similarly, the cognitive screening tests were administered by trained research  
30  
31 psychologists blinded to patients' NIHSS and mRS scores. The patients' functional outcome  
32  
33 was defined by the continuous scores of mRS.  
34

### 35 **Statistical analyses**

37 Between-group differences were examined using independent-sample  $t$  test for quantitative  
38  
39 variables and Pearson's  $\chi^2$  test for categorical variables. Hierarchical regression analyses  
40  
41 were conducted to examine the incremental contribution of baseline MMSE and MoCA  
42  
43 compared with the baseline NIHSS in predicting functional outcomes defined by mRS scores  
44  
45 at 3–6 months after stroke. In the initial analysis, the clinically-relevant or significant  
46  
47 covariates (i.e., age, sex, years of education, number of cardiovascular risk factors, premorbid  
48  
49 and baseline mRS) were entered in the first block. The cognitive screening variables (MMSE  
50  
51 or MoCA) at baseline were entered in the second block and the NIHSS scores at baseline  
52



1  
2  
3  
4  
5  
6  
7 were entered in the third block (Model A1 and B1 for MMSE and MoCA, respectively).  
8  
9 Subsequently, the order of entry was altered, with baseline NIHSS scores entered in the  
10  
11 second block and either baseline MMSE or MoCA entered at the third block (Model A2 and  
12  
13 B2 for MMSE and MoCA, respectively). In order to explore predictive value in patients with  
14  
15 differing stroke severity, we dichotomized the baseline NIHSS scores using a median split  
16  
17 and repeated these analyses.

18 All statistical analyses were performed with IBM SPSS Statistics Version 20.0 for  
19  
20 Windows.

## 21 22 23 24 **RESULTS**

### 25 26 **Subject characteristics**

27 The recruited patients were mostly Chinese (70.3%) and male (69.8%), with a mean age of  
28  
29 59.8 (11.6) years and a mean of 7.7 (4.3) years of formal education. Most patients (79.8%)  
30  
31 had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median  
32  
33 premorbid mRS =0). The median interval between the stroke or TIA event and assessment  
34  
35 was 2 days (range: 0–14).

36  
37 At 3–6 months following the index event, patients who were lost to follow-up ( $n=12$ )  
38  
39 were younger and their clinical condition was stabilized faster than those who completed the  
40  
41 follow-up (age:  $52.8\pm 12.9$  vs  $60.0\pm 11.5$ ,  $p=0.03$ ; interval days:  $2.91\pm 2.31$  vs  $2.08\pm 0.90$ ,

42  
43  $p=0.01$ ). We defined favorable functional outcome as mRS score  $\leq 1$  and poor functional  
44  
45 outcome as mRS score  $\geq 2$ . This dichotomized mRS scores for favorable and poor functional  
46  
47 outcome is commonly used and is in keeping with the recommendation from previous  
48  
49 analyses (9). The majority of the patients ( $n=252$ , 64.9%) had good functional outcomes  
50  
51 (mRSscore  $\leq 1$ ) while approximately one third of the patients ( $n=136$ , 35.1%) had poor  
52

1  
2  
3  
4  
5  
6  
7 functional outcomes (mRS score  $\geq 2$ ). Patients with poor functional outcome were  
8 significantly older, women, of Malay ethnicity, less educated, more neurologically impaired  
9 with poorer premorbid and baseline functioning, and assessed later following cerebrovascular  
10 event. They also had more stroke classification of large artery occlusion and cardioembolic  
11 stroke, as well as higher number of cardiovascular risk factors. In addition, patients with  
12 poorer functional outcome had significantly lower scores of the MMSE and the MoCA. The  
13 population characteristics of patients with favorable and poor functional outcomes can be  
14 found in Table 1. 136 (35.1%) of patients had poor functional outcomes defined by mRS  
15 score  $> 2$  on follow up. The population characteristics can be found in Table 1.  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 **The Predictive Ability of the MoCA, MMSE and NIHSS**

25  
26 Using hierarchical regression analyses and controlling for baseline characteristics, the MMSE,  
27 MoCA and NIHSS—as singular measures—predicted mRS scores at 3–6 months after stroke  
28 (R<sup>2</sup> changes of 0.012, 0.007 and 0.043, with *p*-values 0.004, 0.029 and  $< 0.001$ , respectively;  
29 Table 2). Baseline MMSE scores added a small but statistically significant prediction of  
30 functional outcomes in addition to baseline NIHSS scores, while baseline MoCA scores did  
31 not (MMSE: R<sup>2</sup>changes=0.006, *p*=0.03; MoCA: R<sup>2</sup>changes= 0.004, *p*=0.083).  
32  
33  
34  
35  
36

37 Using a median split of baseline NIHSS scores at 2, patients with NIHSS scores  $\leq 2$   
38 (median =1, range 0–2) were defined as having less severe stroke and those with NIHSS  
39 score  $> 2$  (median = 5, range 3–18) were defined as having more severe stroke. As shown in  
40 Table 3, in patients with NIHSS score  $> 2$ , both baseline MMSE and MoCA had a significant  
41 and considerable incremental prediction for functional outcomes at 3–6 months in addition to  
42 baseline NIHSS scores (MMSE: R<sup>2</sup>changes=0.021, *p*=0.010; MoCA: R<sup>2</sup>changes=0.017,  
43 *p*=0.021), while neither baseline neurocognitive measure nor baseline NIHSS showed an  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 incremental prediction for functional outcome in patients with less severe stroke (NIHSS  
8 score  $\leq 2$ ).  
9

## 10 11 12 **DISCUSSION**

13  
14 Cognitive screening at the subacute stroke phase can predict functional outcome at early  
15 convalescent stroke phase independently. Baseline MMSE scores add a small incremental  
16 prediction to baseline stroke severity scores for functional outcomes at 3-6 months in stroke  
17 patients. Additionally, Unexpectedly, in patients with more severe stroke defined by baseline  
18 NIHSS score  $\geq 2$ , both baseline MMSE and MoCA improve the predictive value of stroke  
19 severity scores for functional outcome 3–6 months later. However, the incremental predictive  
20 value of the MMSE and MoCA is relatively smaller than the NIHSS.  
21  
22  
23  
24  
25  
26  
27

28 The contributions of our study are three-fold. First, our finding that neurocognitive  
29 status at the subacute stroke phase predicts functional outcome at 3–6 months is novel and  
30 consistent with previous studies in inpatient rehabilitation ~~{(1, 2)}~~ and at 13 months after  
31 stroke ~~(3, 4)~~. Second, MMSE scores at baseline add a small incremental prediction to  
32 baseline stroke severity scores for functional outcomes 3-6 months later. Third, both baseline  
33 MMSE and MoCA showed a considerable incremental effect to the baseline NIHSS scores in  
34 predicting functional outcomes in patients with more severe stroke (NIHSS $>2$ ) while neither  
35 neurocognitive measure nor stroke severity score at baseline was predictive for functional  
36 outcome in patients with less severe stroke (NIHSS score  $\leq 2$ ). This may be explained by the  
37 higher recovery potential of patients with more neurological deficits compared to patients  
38 with less severe deficits.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 There are several strengths of our study. First, we examined the prognostic value of  
50 NIHSS and cognitive status by systematically assessing baseline values individually and in  
51  
52

1  
2  
3  
4  
5  
6  
7 combination in predicting patients' mRS scores 3–6 month after stroke. Although previous  
8 studies that investigated the predictive power of cognition included baseline NIHSS as a  
9 control variable (along with other baseline characteristics), they did not explore the role of  
10 baseline NIHSS as a predictor itself (1-3). [1-3] Second, we chose the 3–6 month follow-up  
11 period because prognosis of functional recovery can be made reliably within 12 weeks after  
12 stroke (10), [9] and patients were more likely to resume their daily activities and usual roles  
13 within this time frame. Therefore, the findings established in this study can guide early  
14 intervention from baseline to 3-6 months after stroke. Third, we examined the predictive  
15 ability of neurocognitive status and stroke severity measures at baseline for functional  
16 outcome at 3-6 months in patients with differing stroke severity.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26 There are several limitations of this study. First, Our results may not be  
27 generalizable as the majority of patients had less severe stroke, nevertheless, a third had poor  
28 functional outcomes 3–6 months after stroke so better prognostic tools are required. Second,  
29 We employed cognitive screening tests at baseline rather than formal neuropsychological  
30 assessments, for their brevity and utility by non-specialist personnel. Third, We did not  
31 examine rehabilitation services systematically as this -information was not collected study  
32 was designed to investigate cognitive outcomes after stroke. However, all patients received  
33 standard rehabilitation according to the institutional pathway. In addition Fourth, the mRS has  
34 been criticized for its lack of specificity (5), [5] however, it is a summary of outcomes in  
35 functioning and has been widely used in clinical trials as a primary efficacy measure. Last,  
36 we did not consider other predictive scores (e.g., PLAN score (11), iScore (12), six simple  
37 variable (13) and five simple variable scores (14)) for our models primarily due to the  
38 following reasons: 1) None of these scores include a cognitive measure.; 2) PLAN scores are  
39 developed using more severe functional outcome measure, such as mRS scores of 5 to 6 at

1  
2  
3  
4  
5  
6  
7 discharge. Similarly, iScore has been used to estimate poor functional outcome defined by  
8 mRS 3 to 5. ; 3) Six simple variable and five simple variable scores require Glasgow Coma  
9 Scale which we did not collect in this study. Therefore, we are unable to adopt these models  
10 to predict functional outcome in this study. However, in line with our aims, we included  
11 significant and clinically relevant predictors as control variables (age, sex, education,  
12 composite of cardiovascular risk factors, premorbid mRS and baseline mRS) in our models.

13  
14  
15  
16  
17  
18 In conclusion, 4.3% of the functional outcome after 3-6 months can be predicted early  
19 after admission by NIHSS, with its many functional and only few cognitive items. Premorbid  
20 and baseline factors alone however, explain almost half of the variance. In addition,  
21 neurocognitive status at the subacute stroke phase is independently predictive of  
22 functioning at early convalescent stroke phase. Baseline MMSE scores can add incremental  
23 prediction to baseline stroke severity score for functional outcome 3-6 months later.

24  
25  
26  
27  
28  
29 Moreover, in patients with more recovery potential, both baseline MMSE and MoCA can  
30 improve baseline stroke severity score in predicting functional outcomes 3–6 months later.

31  
32  
33  
34 We have previously shown that these screening tests administered at the subacute stroke  
35 phase could also predict cognitive outcomes 3–6 months later (6).<sup>{6}</sup> In addition, MoCA  
36 administration has been reported to be applicable to the majority of acute stroke patients  
37 (ischemic or hemorrhagic) (82.5%), and therefore feasible to be used in acute stroke phase  
38 (15). Therefore, the predictive value and brevity of the MMSE and MoCA warrants their  
39 routine use in the subacute stroke phase in clinical service and early acute stroke trials.

40  
41  
42  
43  
44  
45 However, the current instruments (NIHSS in combination with MMSE or MoCA) could only  
46 predict for 51% of the functional outcome. Therefore, it would be helpful if a better  
47 prognostic tool can improve the prediction for functional outcome to 70%-80%.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Future studies may establish a modified scale combining the NIHSS and items from the MMSE and MoCA to improve the predictive ability for functional outcome.

For peer review only




Table 1. Population characteristics according to the functional outcome [defined by mRS scores at 3-6 months after stroke](#)

Characteristics N (%)	mRS 0- <del>1</del> <sup>2</sup>		mRS <del>≥</del> <sup>≥</sup> 2		Univariate Analysis <i>P</i>
	<i>(n = 252)</i>		<i>(n = 136)</i>		
Age, mean (SD)	57.9	(10.8)	63.8	(11.8)	<0.001
Gender, female*	68	(27.0%)	52	(38.2%)	0.02
Education, y (mean, SD)	9.8	(4.3)	6.3	(3.7)	<0.001
Ethnicity					0.0 <del>3</del> <sup>9</sup>
<i>Chinese</i>	188	(74.6%)	87	(64.0%)	
<i>Malay</i>	40	(15.9%)	36	(26.5%)	
<i>Indian and others</i>	<del>2</del> <sup>24</sup>	<del>(0.8%)</del> <sup>(9.58.7%)</sup>	<del>1</del> <sup>23</sup>	<del>(0.7%)</del> <sup>(9.68.8%)</sup>	
<i>Others</i>	<del>2</del>	<del>(0.8%)</del>	<del>1</del>	<del>(0.7%)</del>	
Stroke classification					≤0.001
<i>SAO</i>	114	(45.2%)	60	(44.1%)	
<i>LAA</i>	29	(11.5%)	30	(22.1%)	

Characteristics N (%)	mRS 0- <del>1</del> <sub>2</sub>		mRS <del>&gt;</del> <sub>2</sub>		Univariate Analysis
	(n = 252)		(n = 136)		P
CE	31	(12.3%)	25	(18.4%)	
UND <u>and</u> OC	<del>12</del> <sub>4</sub>	(4. <del>84</del> <sub>9</sub> %)	<del>87</del> <sub>7</sub>	(5. <del>94</del> <sub>5</sub> %)	
<del>OE</del>	<del>1</del>	( <del>0.4</del> <sub>0</sub> %)	<del>1</del>	( <del>0.7</del> <sub>0</sub> %)	
TIA	66	(26.2%)	13	(9.6%)	
NIHSS ( <del>median mean, SD</del> ) <sup>*</sup>	<del>1.46</del> <sub>4</sub>	( <del>1.83</del> <sub>3</sub> )	<del>5.04</del> <sub>4</sub>	( <del>3.68</del> <sub>6</sub> )	<0.001
Premorbid mRS ( <del>median median</del> )	<del>0.06</del> <sub>6</sub>	( <del>0.29</del> <sub>9</sub> )	<del>0.54</del> <sub>4</sub>	( <del>1.05</del> <sub>5</sub> )	<0.001
Baseline mRS ( <del>median median</del> ) <sup>*</sup>	<del>1.28</del> <sub>8</sub>	( <del>1.20</del> <sub>0</sub> )	<del>3.04</del> <sub>4</sub>	( <del>1.21</del> <sub>1</sub> )	<0.001
Mean interval ( <u>days</u> ) between stroke/TIA and assessment	2.4	(2.0)	3.8	(2.5)	<0.001
Cognitive screening tests					
MMSE ( <i>mean, SD</i> )	25.7	(3.3)	22.6	(4.3)	<0.001
MoCA ( <i>mean, SD</i> )	22.0	(4.8)	18.1	(5.5)	<0.001
Number of cardiovascular risk factors (median)	2		3		<0.001

15



Characteristics N (%)	mRS 0-1 <del>2</del>		mRS <del>1</del> ≥2		Univariate Analysis
	(n = 252)		(n = 136)		<i>P</i>
Recurrent vascular events (no., %)	10	(4.0%)	8	(6.0%)	0.37

\**P*<0.050 for logistic regression for binary outcome of mRS scores of 0-1 and ≥2.

**mRS** = modified Rankin scale; **SD**= Standard Deviations; **SAO** = small artery occlusion; **LAA**= large artery atherosclerosis; **CE** = cardioembolism; **UND** = undetermined etiology; **OC** = other determined etiology; **TIA**= transient ischemic attack; **NIHSS** = National Institute of Health Stroke Score; **MMSE**=Mini-Mental State Examination; **MoCA**=Montreal Cognitive Assessment.

Table 2. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS scores

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	54.10	<0.001
A1	2	Baseline MMSE	-0.1 (0.031)	0.47	0.012	8.48	0.004
	3	Baseline NIHSS	0.3 (<0.001)	0.51	0.038	29.00	<0.001
A2	2	Baseline NIHSS	0.3 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MMSE	-0.1 (0.031)	0.51	0.006	4.71	0.031
B1	2	Baseline MoCA	-0.08 (0.083)	0.47	0.007	4.80	0.029
	3	Baseline NIHSS	0.31 (<0.001)	0.51	0.040	31.10	<0.001
B2	2	Baseline NIHSS	0.31 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MoCA	-0.08 (0.083)	0.51	0.004	3.02	0.083

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

Table 3. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS for subsample of patients with NIHSS scores >2 at baseline

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	21.68	<0.001
A1	2	Baseline MMSE	-0.18 (0.010)	0.49	0.036	10.94	0.001
	3	Baseline NIHSS	0.22 (0.001)	0.53	0.034	11.07	0.001
A2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MMSE	-0.18 (0.010)	0.53	0.021	6.83	0.010
B1	2	Baseline MoCA	-0.16 (0.021)	0.49	0.029	8.51	0.004
	3	Baseline NIHSS	0.22 (0.001)	0.52	0.040	12.07	0.001
B2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MoCA	-0.16 (0.021)	0.52	0.017	5.42	0.021

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

1  
2  
3  
4  
5  
6  
7 **Acknowledgments:** The authors thank all participants for their involvement. They also thank  
8 the research team from NUHS Memory Aging and Cognition Centre for data collection and  
9 the NUHS Medical Publications Support Unit for its editorial support.

10  
11  
12 **Contributors:** Y. Dong drafted the original manuscript. Statistical analysis was conducted by  
13 Ms. Y Dong with the guidance from Dr. J Crawford. All authors contributed to one of: study  
14 design, conceptualization, analysis, interpretation of the data, drafting or revision of the  
15 manuscript for intellectual content.

16  
17  
18  
19  
20 **Funding:** This work was supported by a Center Grant from the National Medical Research  
21 Council (NMRC/CG/NUHS/2010). Y. Dong has received research support by a NMRC  
22 fellowship training award.

23  
24  
25  
26  
27 **Competing interests:** None.

28  
29  
30 **Patient consent:** Obtained.

31  
32 **Ethics approval:** National Healthcare Group Domain-Specific Ethics Review Board.

33  
34  
35 **Provenance and peer review:** Not commissioned; externally peer reviewed.

36  
37  
38 **Data sharing statement:** No additional data are available.

## REFERENCES

- 1 Toglia J, Fitzgerald KA, O'Dell MW, *et al.* The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. *Arch Phys Med Rehabil* 2011;**92**:792–8.
- 2 Zwecker M, Levenkrohn S, Fleisig Y, *et al.* Mini-Mental State Examination, Cognitive FIM Instrument, and the Loewenstein Occupational Therapy Cognitive Assessment: relation to functional outcome of stroke patients. *Arch Phys Med Rehabil* 2002;**83**:342–5.
- 3 Wagle J, Farner L, Flekkøy K, *et al.* Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. *Dement Geriatr Cogn Disord* 2011;**31**:379–7.
- 4 Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. *Stroke* 2012;**43**:560–2.
- 5 Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;**5**:603–12.
- 6 Dong Y, Venketasubramanian N, Chan BP, *et al.* Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3-6 months after stroke. *J Neurol Neurosurg Psychiatry* 2012;**83**:580–5.
- 7 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;**12**:189–98.
- 8 Nasreddine ZS, Phillips NA, Bédirian V, *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;**53**:695–9.
- 9 [Weisscher, N, Vermeulen M, Ross YB, \*et al.\* What should be defined as good outcome in stroke trials: a modified Rankin score of 0-1 or 0-2? \*J Neurol\* 2008;\*\*255\*\*:867-874.](#)

Formatted: Font: Bold

- 1  
2  
3  
4  
5  
6  
7 [10 Jørgensen HS, Nakayama H, Raaschou HO, et al. Outcome and time course of recovery](#)  
8 [in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. \*Arch Phys\*](#)  
9 [Med Rehabil 1995;\*\*76\*\*:406-12.](#)
- 10  
11  
12 [11 O'Donnell MJ, Fang J, D'Uva C, et al. The PLAN Score: A bedside prediction rule for](#)  
13 [death and severe disability following acute ischemic stroke. \*Arch Intern Med\*](#)  
14 [2012;\*\*172\*\*:1548-1556.](#)
- 15  
16  
17  
18 [12 Saposnik G, Raptis S, Kapral MK, et al. The iScore predicts poor functional outcomes](#)  
19 [early after hospitalization for an acute ischemic stroke. \*Stroke\* 2011;\*\*42\*\*:3421-3428.](#)
- 20  
21  
22 [13 Reid JM, Gubitz GJ, Dai D, et al. External validation of a six simple variable model of](#)  
23 [stroke outcome and verification in hyper-acute stroke. \*J Neurol Neurosurg Psychiatry\*](#)  
24 [2007;\*\*78\*\*:1390-1391.](#)
- 25  
26  
27  
28 [14 Ayis SA, Coker B, Rudd AG, et al. Predicting independent survival after stroke: a](#)  
29 [European study for the development and validation of a standardised stroke scales and](#)  
30 [prediction models of outcome. \*J Neurol Neurosurg Psychiatry\* 2013;\*\*84\*\*:288-296.](#)
- 31  
32  
33  
34 [15 Pasi M, Salvadori E, Poggesi A, et al. Factors predicting the Montreal cognitive](#)  
35 [assessment \(MoCA\) applicability and performances in a stroke unit. \*J Neurol\*](#)  
36 [2013;\*\*260\*\*:1518-1526.](#)
- 37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after mild stroke and transient ischemic attack: an observational study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003105.R2
Article Type:	Research
Date Submitted by the Author:	02-Aug-2013
Complete List of Authors:	Dong, Yanhong; National University Health System, Pharmacology Slavin, Melissa; The University of New South Wales Chan, Bernard; National University Health System, Medicine Venkatasubramanian, Narayanaswamy; National University Health System, Memory Aging and Cognition Centre, Department of Pharmacology; National University of Singapore, Division of Neurology, University Medicine Cluster Sharma, Vijay; National University Health System, Medicine Crawford, John; The University of New South Wales Collinson, Simon; National University of Singapore, Psychology Sachdev, Perminder; University of New South Wales, School of Psychiatry chen, christopher; National University Health System, Pharmacology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Geriatric medicine
Keywords:	Stroke < NEUROLOGY, GERIATRIC MEDICINE, REHABILITATION MEDICINE

SCHOLARONE™  
Manuscripts

Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after mild stroke and transient ischemic attack: an observational study

YanHong Dong, MAppSci,<sup>1,2,3</sup> Melissa Jane Slavin, PhD,<sup>3,4</sup> Bernard Poon-Lap Chan, MD,<sup>5</sup>

Narayanaswamy Venketasubramanian, MD,<sup>1,5,6</sup> Vijay Kumar Sharma, MD,<sup>5</sup> John D Crawford, PhD,<sup>3</sup> Simon Lowes Collinson, PhD,<sup>7</sup> Perminder Sachdev, MD, PhD,<sup>3</sup> Christopher Li-Hsian Chen, MD.<sup>1,2</sup>

<sup>1</sup>Memory Aging and Cognition Centre, Department of Pharmacology, National University Health System, Singapore

<sup>2</sup>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>3</sup>Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>4</sup>Dementia Collaborative Research Centre – Assessment and Better Care, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>5</sup>Department of Medicine, National University Health System, Singapore

<sup>6</sup>Neuroscience Clinic, Raffles Hospital, Singapore

<sup>7</sup>Department of Psychology, National University of Singapore, Singapore

#### **CORRESPONDING AUTHOR**

Dr C L-H Chen

Department of Pharmacology

National University Health System



1  
2  
3 Clinical Research Centre, MD11, Level 5, #05-9  
4

5  
6 10 Medical Drive  
7

8  
9 Singapore 117597  
10

11  
12 Phone: +65 65165885  
13

14  
15 Fax: +65 68724101  
16

17  
18 Email: [phccclh@nus.edu.sg](mailto:phccclh@nus.edu.sg)  
19

20  
21 Number of words in abstract: 283 words  
22

23  
24 Number of words in manuscripts: 2378 words  
25

26  
27 Tables: 3  
28

29  
30 Figures: 0  
31

32  
33 Short title: Neurocognitive status predicts functional outcome after stroke  
34

35  
36 Key Words: Stroke, Predictive value of tests, Cognition, NIHSS, Functional outcome  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** To investigate the prognostic value of the neurocognitive status measured by screening instruments, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), obtained at the subacute stroke phase or the baseline ( $\leq 2$  weeks), for functional outcome 3–6 months later.

**Design:** Prospective observational study.

**Setting:** Tertiary stroke neurology service.

**Participants:** 400 patients with a recent ischemic stroke or transient ischemic attack (TIA) received NIHSS, MoCA and MMSE at baseline and were followed up at 3–6 months later.

**Primary outcome measures:** At 3–6 months following index event, functional outcome was measured by the modified Rankin Scale (mRS) scores.

**Results:** Most patients (79.8%) had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median premorbid mRS =0), while a minority of patients had TIA (20.3%). Baseline NIHSS, MMSE and MoCA scores individually predicted mRS scores at 3–6 months, with NIHSS being the strongest predictor (NIHSS:  $R^2$ change=0.043,  $p<0.001$ ). Moreover, baseline MMSE scores had a small but statistically significant incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months, while baseline MoCA scores did not [MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ]. However, in patients with more severe stroke at baseline (defined as NIHSS $>2$ ), both baseline MoCA and MMSE had significant and moderately large incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months [MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  $p=0.021$ ].

1  
2  
3 **Conclusion:** Cognitive screening at the subacute stroke phase can predict functional outcome  
4 independently and improve the predictive value of stroke severity scores for functional  
5 outcome 3–6 months later, particularly in patients with more severe stroke.  
6  
7  
8

9  
10 **ARTICLE SUMMARY**

11 **Article focus**

- 12  
13
- 14 • The prognostic value of neurocognitive status measured by brief screening  
15 instruments, the MoCA and the MMSE, individually and in combination with the  
16 stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), at  
17 subacute stroke phase for functional outcomes at 3–6 months is unknown.  
18  
19
  - 20 • We examined the predictive ability of MMSE and MoCA individually and in  
21 combination with the NIHSS for functional outcome 3–6 months after mild stroke and  
22 transient ischemic attack.  
23  
24
  - 25 • We also explored the predictive ability of these measures in patients with differing  
26 stroke severity.  
27  
28  
29  
30  
31  
32  
33

34 **Key messages**

- 35  
36
- 37 • Cognitive screening at the subacute stroke phase can predict functional outcome  
38 independently. Neurocognitive status measured by baseline MMSE scores adds a  
39 small incremental prediction to baseline stroke severity scores for functional  
40 outcomes at 3-6 months in stroke patients.  
41  
42  
43  
44
  - 45 • Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ ,  
46 neurocognitive status measured by both baseline MMSE and MoCA improve the  
47 predictive value of stroke severity scores for functional outcome 3–6 months later.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strength and limitations of this study

- The main strength of this study is that we examined the prognostic value of neurocognitive status (MoCA and MMSE) and stroke severity (NIHSS) at subacute stroke phase systematically as a singular measure and in combination for mRS scores 3–6 month later in a large sample of stroke patients and in patients with differing stroke severity.
- An additional strength is the choice of 3–6 month follow-up because patients were more likely to resume their daily activities and usual roles within this time frame. Hence, the findings established in this study can guide early intervention from baseline to 3-6 months after stroke.
- The limitation of this study is that we did not systematically examine rehabilitation services provided for patients from subacute stroke phase to 3-6 months follow-up.

## INTRODUCTION

It is important for early intervention and focused management to have instruments available during the subacute stroke phase for predicting functional outcome 3–6 months later.

Cognitive performance measured by the Montreal Cognitive Assessment (MoCA) and the Mini-mental State Examination (MMSE) administered at the subacute stroke phase predicted patients' functional outcomes at inpatient discharge (1, 2). Furthermore, patients' post-stroke cognitive functioning measured by a brief neuropsychological battery 2–3 weeks following stroke predicted their functional outcomes 13 months later (3). No study yet has investigated the utility of patients' neurocognitive status at the subacute stroke phase for predicting functional outcome at 3–6 months. A widely used stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), administered at the subacute stroke phase is predictive of patients' functional outcomes 3–6 months later (4), but has limited representation of cognitive function (5). Hence, whether the NIHSS and neurocognitive status at baseline are independently predictive or have additive predictive value for functional outcomes at 3–6 months is unknown.

We therefore examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS at the subacute stroke phase for functional outcome 3–6 months later. In addition, we explored the predictive ability of these measures in patients with differing stroke severity.

## METHODS

### Subjects

The methodology of this study has been described previously (6). [6] Briefly, we recruited 400 consecutive patients ( $\geq 21$  years old) with a recent ischemic stroke or transient ischemic

1  
2  
3 attack (TIA) ( $\leq 14$  days) during their inpatient admission (subacute stroke phase or baseline)  
4  
5 at the National University Health System in Singapore. Patients were excluded if they had a  
6  
7 major physical disability or an active psychiatric disorder that would impede cognitive testing.  
8

### 9 10 **Standard protocol approvals and patient consent**

11 This study was approved by the National Healthcare Group Domain-Specific Review Board  
12  
13 (DSRB), and was conducted in conformity with the Declaration of Helsinki. Written  
14  
15 informed consent was obtained from all participants and/or legally acceptable representatives.  
16  
17

### 18 19 **Procedures**

20 Patients were assessed using the NIHSS, modified Rankin Scale (mRS) (premorbid and  
21  
22 baseline functioning), MMSE (7) and MoCA (8) at baseline. In addition, their mRS scores  
23  
24 were collected at 3–6 months later. The NIHSS and mRS were administered by certified  
25  
26 research personnel blinded to patients' neurocognitive status at baseline and 3-6 months  
27  
28 follow-up. Similarly, the cognitive screening tests were administered by trained research  
29  
30 psychologists blinded to patients' NIHSS and mRS scores. The patients' functional outcome  
31  
32 was defined by the continuous scores of mRS.  
33  
34

### 35 36 37 **Statistical analyses**

38 Between-group differences were examined using independent-sample *t* test for quantitative  
39  
40 variables and Pearson's  $\chi^2$  test for categorical variables. Hierarchical regression analyses  
41  
42 were conducted to examine the incremental contribution of baseline MMSE and MoCA  
43  
44 compared with the baseline NIHSS in predicting functional outcomes defined by mRS scores  
45  
46 at 3–6 months after stroke. In the initial analysis, the clinically-relevant or significant  
47  
48 covariates (i.e., age, sex, years of education, number of cardiovascular risk factors, premorbid  
49  
50 and baseline mRS) were entered in the first block. The cognitive screening variables (MMSE  
51  
52 or MoCA) at baseline were entered in the second block and the NIHSS scores at baseline  
53  
54  
55

1  
2  
3 were entered in the third block (Model A1 and B1 for MMSE and MoCA, respectively).  
4  
5 Subsequently, the order of entry was altered, with baseline NIHSS scores entered in the  
6  
7 second block and either baseline MMSE or MoCA entered at the third block (Model A2 and  
8  
9 B2 for MMSE and MoCA, respectively). In order to explore predictive value in patients with  
10  
11 differing stroke severity, we dichotomized the baseline NIHSS scores using a median split  
12  
13 and repeated these analyses.  
14

15  
16 All statistical analyses were performed with IBM SPSS Statistics Version 20.0 for  
17  
18 Windows.  
19

## 20 21 22 23 **RESULTS**

### 24 25 **Subject characteristics**

26  
27 The recruited patients were mostly Chinese (70.3%) and male (69.8%), with a mean age of  
28  
29 59.8 (11.6) years and a mean of 7.7 (4.3) years of formal education. Most patients (79.8%)  
30  
31 had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median  
32  
33 premorbid mRS =0), while a minority of patients had TIA (20.3%). The median interval  
34  
35 between the stroke or TIA event and assessment was 2 days (range: 0–14).  
36  
37

38  
39 At 3–6 months following the index event, patients who were lost to follow-up ( $n=12$ )  
40  
41 were younger and their clinical condition was stabilized faster than those who completed the  
42  
43 follow-up (age:  $52.8\pm 12.9$  vs  $60.0\pm 11.5$ ,  $p=0.03$ ; interval days:  $2.91\pm 2.31$  vs  $2.08\pm 0.90$ ,  
44  
45  $p=0.01$ ). We defined favorable functional outcome as mRS score  $\leq 1$  and poor functional  
46  
47 outcome as mRS score  $\geq 2$ . This dichotomized mRS scores for favorable and poor functional  
48  
49 outcome is commonly used and is in keeping with the recommendation from previous  
50  
51 analyses (9). The majority of the patients ( $n=252$ , 64.9%) had good functional outcomes  
52  
53 (mRSscore  $\leq 1$ ) while approximately one third of the patients ( $n=136$ , 35.1%) had poor  
54  
55

1  
2  
3 functional outcomes (mRS score  $\geq 2$ ). Patients with poor functional outcome were  
4  
5 significantly older, women, of Malay ethnicity, less educated, more neurologically impaired  
6  
7 with poorer premorbid and baseline functioning, and assessed later following cerebrovascular  
8  
9 event. They also had more stroke classification of large artery occlusion and cardioembolic  
10  
11 stroke, as well as higher number of cardiovascular risk factors. In addition, patients with  
12  
13 poorer functional outcome had significantly lower scores of the MMSE and the MoCA. The  
14  
15 population characteristics of patients with favorable and poor functional outcomes can be  
16  
17 found in Table 1.  
18  
19

### 20 **The Predictive Ability of the MoCA, MMSE and NIHSS**

21  
22 Using hierarchical regression analyses and controlling for baseline characteristics, the MMSE,  
23  
24 MoCA and NIHSS—as singular measures—predicted mRS scores at 3–6 months after stroke  
25  
26 ( $R^2$  changes of 0.012, 0.007 and 0.043, with  $p$ -values 0.004, 0.029 and  $<0.001$ , respectively;  
27  
28 Table 2). Baseline MMSE scores added a small but statistically significant prediction of  
29  
30 functional outcomes in addition to baseline NIHSS scores, while baseline MoCA scores did  
31  
32 not (MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ).  
33  
34  
35

36 Using a median split of baseline NIHSS scores at 2, patients with NIHSS scores  $\leq 2$   
37  
38 (median =1, range 0–2) were defined as having less severe stroke and those with NIHSS  
39  
40 score  $>2$  (median = 5, range 3–18) were defined as having more severe stroke. As shown in  
41  
42 Table 3, in patients with NIHSS score  $>2$ , both baseline MMSE and MoCA had a significant  
43  
44 and considerable incremental prediction for functional outcomes at 3-6 months in addition to  
45  
46 baseline NIHSS scores (MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  
47  
48  $p=0.021$ ), while neither baseline neurocognitive measure nor baseline NIHSS showed an  
49  
50 incremental prediction for functional outcome in patients with less severe stroke (NIHSS  
51  
52 score  $\leq 2$ ).  
53  
54  
55  
56  
57  
58  
59  
60



## DISCUSSION

Cognitive screening at the subacute stroke phase can predict functional outcome at early convalescent stroke phase independently. Baseline MMSE scores add a small incremental prediction to baseline stroke severity scores for functional outcomes at 3-6 months in stroke patients. Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ , both baseline MMSE and MoCA improve the predictive value of stroke severity scores for functional outcome 3–6 months later. However, the incremental predictive value of the MMSE and MoCA is relatively smaller than the NIHSS.

The contributions of our study are three-fold. First, our finding that neurocognitive status at the subacute stroke phase predicts functional outcome at 3–6 months is novel and consistent with previous studies in inpatient rehabilitation (1, 2) and at 13 months after stroke (3). Second, MMSE scores at baseline add a small incremental prediction to baseline stroke severity scores for functional outcomes 3-6 months later. Third, both baseline MMSE and MoCA showed a considerable incremental effect to the baseline NIHSS scores in predicting functional outcomes in patients with more severe stroke (NIHSS $>2$ ) while neither neurocognitive measure nor stroke severity score at baseline was predictive for functional outcome in patients with less severe stroke (NIHSS score  $\leq 2$ ). This may be explained by the higher recovery potential of patients with more neurological deficits compared to patients with less severe deficits.

There are several strengths of our study. First, we examined the prognostic value of NIHSS and cognitive status by systematically assessing baseline values individually and in combination in predicting patients' mRS scores 3–6 month after stroke. Although previous studies that investigated the predictive power of cognition included baseline NIHSS as a control variable (along with other baseline characteristics), they did not explore the role of

1  
2  
3 baseline NIHSS as a predictor itself (1-3). Second, we chose the 3–6 month follow-up period  
4  
5 because prognosis of functional recovery can be made reliably within 12 weeks after stroke  
6  
7 (10), and patients were more likely to resume their daily activities and usual roles within this  
8  
9 time frame. Therefore, the findings established in this study can guide early intervention from  
10  
11 baseline to 3-6 months after stroke. Third, we examined the predictive ability of  
12  
13 neurocognitive status and stroke severity measures at baseline for functional outcome at 3-6  
14  
15 months in patients with differing stroke severity.  
16  
17

18  
19 There are several limitations of this study. First, our results may not be generalizable  
20  
21 as the majority of patients had less severe stroke, nevertheless, a third had poor functional  
22  
23 outcomes 3–6 months after stroke so better prognostic tools are required. Second, we  
24  
25 employed cognitive screening tests at baseline rather than formal neuropsychological  
26  
27 assessments, for their brevity and utility by non-specialist personnel. Third, we did not  
28  
29 examine rehabilitation services systematically as this information was not collected. However,  
30  
31 all patients received standard rehabilitation according to the institutional pathway. Fourth, the  
32  
33 mRS has been criticized for its lack of specificity (5), however, it is a summary of outcomes  
34  
35 in functioning and has been widely used in clinical trials as a primary efficacy measure. Last,  
36  
37 we did not consider other predictive scores (e.g., PLAN score (11), iScore (12), six simple  
38  
39 variable (13) and five simple variable scores (14)) for our models primarily due to the  
40  
41 following reasons: 1) None of these scores include a cognitive measure.; 2) PLAN scores are  
42  
43 developed using more severe functional outcome measure, such as mRS scores of 5 to 6 at  
44  
45 discharge. Similarly, iScore has been used to estimate poor functional outcome defined by  
46  
47 mRS 3 to 5. ; 3) Six simple variable and five simple variable scores require Glasgow Coma  
48  
49 Scale which we did not collect in this study. Therefore, we are unable to adopt these models  
50  
51 to predict functional outcome in this study. However, in line with our aims, we included  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 significant and clinically relevant predictors as control variables (age, sex, education,  
4  
5 composite of cardiovascular risk factors, premorbid mRS and baseline mRS) in our models.  
6  
7 Our prediction models can be applied to patients with mild ischemic stroke and TIA,  
8  
9 especially in those with NIHSS score >2. The routine cognitive screening at subacute stroke  
10  
11 phase with either MoCA or MMSE could add incremental predictive value to the NIHSS of  
12  
13 patients with NIHSS score >2 for functional outcomes at 3-6 months. However, this model  
14  
15 has yet to be validated externally, therefore it may not be generalizable to other stroke  
16  
17  
18  
19 population.

20  
21 In conclusion, 4.3% of the functional outcome after 3-6 months can be predicted early  
22  
23 after admission by NIHSS, with its many functional and only few cognitive items. Premorbid  
24  
25 and baseline factors alone however, explain almost half of the variance. In addition,  
26  
27 neurocognitive status at the subacute stroke phase is independently predictive of functioning  
28  
29 at early convalescent stroke phase. Baseline MMSE scores can add incremental prediction to  
30  
31 baseline stroke severity score for functional outcome 3-6 months later. Moreover, in patients  
32  
33 with more recovery potential, both baseline MMSE and MoCA can improve baseline stroke  
34  
35 severity score in predicting functional outcomes 3-6 months later. We have previously shown  
36  
37 that these screening tests administered at the subacute stroke phase could also predict  
38  
39 cognitive outcomes 3-6 months later (6). In addition, MoCA administration has been reported  
40  
41 to be applicable to the majority of acute stroke patients (ischemic or hemorrhagic)  
42  
43 (82.5%), and therefore feasible to be used in acute stroke phase (15). Therefore, the predictive  
44  
45 value and brevity of the MMSE and MoCA warrants their routine use in the subacute stroke  
46  
47 phase in clinical service and early acute stroke trials. However, the current instruments  
48  
49 (NIHSS in combination with MMSE or MoCA) could only predict for 51% of the functional  
50  
51 outcome. Therefore, it would be helpful if a better prognostic tool can improve the prediction  
52  
53  
54  
55

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

for functional outcome to 70%-80%. Future studies may establish a modified scale combining the NIHSS and items from the MMSE and MoCA to improve the predictive ability for functional outcome.

For peer review only

Table 1. Population characteristics according to the functional outcome defined by mRS scores at 3-6 months after stroke

Characteristics N (%)	mRS 0–1		mRS ≥2		Univariate Analysis
		(n = 252)		(n = 136)	P
Age, mean (SD)	57.9	(10.8)	63.8	(11.8)	<0.001
Gender, female	68	(27.0%)	52	(38.2%)	0.02
Education, y (mean, SD)	9.8	(4.3)	6.3	(3.7)	<0.001
Ethnicity					0.039
<i>Chinese</i>	188	(74.6%)	87	(64.0%)	
<i>Malay</i>	40	(15.9%)	36	(26.5%)	
<i>Indian and others</i>	24	(9.5%)	13	(9.6%)	
Stroke classification					<0.001
<i>SAO</i>	114	(45.2%)	60	(44.1%)	
<i>LAA</i>	29	(11.5%)	30	(22.1%)	
<i>CE</i>	31	(12.3%)	25	(18.4%)	

Characteristics N (%)	mRS 0–1		mRS ≥2		Univariate Analysis
	(n = 252)		(n = 136)		<i>P</i>
<i>UND and OC</i>	12	(4.8%)	8	(5.9%)	
<i>TIA</i>	66	(26.2%)	13	(9.6%)	
NIHSS ( mean, SD)	1.46	(1.83)	5.04	(3.68)	<0.001
Premorbid mRS (median )	0.06	(0.29)	0.54	(1.05)	<0.001
Baseline mRS (median )	1.28	(1.20)	3.04	(1.21)	<0.001
Mean interval (days) between stroke/TIA and assessment	2.4	(2.0)	3.8	(2.5)	<0.001
Cognitive screening tests					
<i>MMSE (mean, SD)</i>	25.7	(3.3)	22.6	(4.3)	<0.001
<i>MoCA (mean, SD)</i>	22.0	(4.8)	18.1	(5.5)	<0.001
Number of cardiovascular risk factors (median)	2		3		<0.001
Recurrent vascular events (no., %)	10	(4.0%)	8	(6.0%)	0.37

Characteristics N (%)	mRS 0–1 (n = 252)	mRS ≥2 (n = 136)	Univariate Analysis <i>P</i>
-----------------------	----------------------	---------------------	---------------------------------

**mRS** = modified Rankin scale; **SD**= Standard Deviations; **SAO** = small artery occlusion; **LAA**= large artery atherosclerosis; **CE** = cardioembolism; **UND** = undetermined etiology; **OC** = other determined etiology; **TIA**= transient ischemic attack; **NIHSS** = National Institute of Health Stroke Score; **MMSE**=Mini-Mental State Examination; **MoCA**=Montreal Cognitive Assessment.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Table 2. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS scores

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	54.10	<0.001
A1	2	Baseline MMSE	-0.1 (0.031)	0.47	0.012	8.48	0.004
	3	Baseline NIHSS	0.3 (<0.001)	0.51	0.038	29.00	<0.001
A2	2	Baseline NIHSS	0.3 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MMSE	-0.1 (0.031)	0.51	0.006	4.71	0.031
B1	2	Baseline MoCA	-0.08 (0.083)	0.47	0.007	4.80	0.029
	3	Baseline NIHSS	0.31 (<0.001)	0.51	0.040	31.10	<0.001
B2	2	Baseline NIHSS	0.31 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MoCA	-0.08 (0.083)	0.51	0.004	3.02	0.083

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.



Table 3. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS for subsample of patients with NIHSS scores >2 at baseline

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	21.68	<0.001
A1	2	Baseline MMSE	−0.18 (0.010)	0.49	0.036	10.94	0.001
	3	Baseline NIHSS	0.22 (0.001)	0.53	0.034	11.07	0.001
A2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MMSE	−0.18 (0.010)	0.53	0.021	6.83	0.010
B1	2	Baseline MoCA	−0.16 (0.021)	0.49	0.029	8.51	0.004
	3	Baseline NIHSS	0.22 (0.001)	0.52	0.040	12.07	0.001
B2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MoCA	−0.16 (0.021)	0.52	0.017	5.42	0.021

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

1  
2  
3 **Acknowledgments:** The authors thank all participants for their involvement. They also thank  
4  
5 the research team from NUHS Memory Aging and Cognition Centre for data collection and  
6  
7 the NUHS Medical Publications Support Unit for its editorial support.  
8

9  
10 **Contributors:** Y. Dong drafted the original manuscript. Statistical analysis was conducted by  
11  
12 Ms. Y Dong with the guidance from Dr. J Crawford. All authors contributed to one of: study  
13  
14 design, conceptualization, analysis, interpretation of the data, drafting or revision of the  
15  
16 manuscript for intellectual content.  
17

18  
19 **Funding:** This work was supported by a Center Grant from the National Medical Research  
20  
21 Council (NMRC/CG/NUHS/2010). Y. Dong has received research support by a NMRC  
22  
23 fellowship training award.  
24

25  
26 **Competing interests:** None.  
27

28  
29 **Patient consent:** Obtained.  
30

31  
32 **Ethics approval:** National Healthcare Group Domain-Specific Ethics Review Board.  
33

34  
35 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
36

37  
38 **Data sharing statement:** No additional data are available.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Toglia J, Fitzgerald KA, O'Dell MW, *et al.* The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. *Arch Phys Med Rehabil* 2011;**92**:792–8.
- 2 Zwecker M, Levenkrohn S, Fleisig Y, *et al.* Mini-Mental State Examination, Cognitive FIM Instrument, and the Loewenstein Occupational Therapy Cognitive Assessment: relation to functional outcome of stroke patients. *Arch Phys Med Rehabil* 2002;**83**:342–5.
- 3 Wagle J, Farner L, Flekkøy K, *et al.* Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. *Dement Geriatr Cogn Disord* 2011;**31**:379–7.
- 4 Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. *Stroke* 2012;**43**:560–2.
- 5 Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;**5**:603–12.
- 6 Dong Y, Venketasubramanian N, Chan BP, *et al.* Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3–6 months after stroke. *J Neurol Neurosurg Psychiatry* 2012;**83**:580–5.
- 7 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;**12**:189–98.
- 8 Nasreddine ZS, Phillips NA, Bédirian V, *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;**53**:695–9.
- 9 Weisscher, N, Vermeulen M, Ross YB, *et al.* What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2? *J Neurol* 2008;**255**:867-874.

- 1  
2  
3 10 Jørgensen HS, Nakayama H, Raaschou HO, *et al.* Outcome and time course of recovery  
4 in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. *Arch Phys*  
5 *Med Rehabil* 1995;**76**:406-12.  
6  
7  
8  
9  
10 11 O'Donnell MJ, Fang J, D'Uva C, *et al.* The PLAN Score: A bedside prediction rule for  
11 death and severe disability following acute ischemic stroke. *Arch Intern Med*  
12 2012;**172**:1548-1556.  
13  
14  
15 12 Saposnik G, Raptis S, Kapral MK, *et al.* The iScore predicts poor functional outcomes  
16 early after hospitalization for an acute ischemic stroke. *Stroke* 2011;**42**:3421-3428.  
17  
18  
19  
20 21 Reid JM, Gubitz GJ, Dai D, *et al.* External validation of a six simple variable model of  
22 stroke outcome and verification in hyper-acute stroke. *J Neurol Neurosurg Psychiatry*  
23 2007;**78**:1390-1391.  
24  
25  
26  
27 28 Ayis SA, Coker B, Rudd AG, *et al.* Predicting independent survival after stroke: a  
29 European study for the development and validation of a standardised stroke scales and  
30 prediction models of outcome. *J Neurol Neurosurg Psychiatry* 2013;**84**:288-296.  
31  
32  
33 34 Pasi M, Salvadori E, Poggesi A, *et al.* Factors predicting the Montreal cognitive  
35 assessment (MoCA) applicability and performances in a stroke unit. *J Neurol*  
36 2013;**260**:1518-1526.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3–6 months after mild stroke and transient ischemic attack: an observational study

YanHong Dong, MAppSci,<sup>1,2,3</sup> Melissa Jane Slavin, PhD,<sup>3,4</sup> Bernard Poon-Lap Chan, MD,<sup>5</sup>

Narayanaswamy Venketasubramanian, MD,<sup>1,5,6</sup> Vijay Kumar Sharma, MD,<sup>5</sup> John D Crawford, PhD,<sup>3</sup> Simon Lowes Collinson, PhD,<sup>7</sup> Perminder Sachdev, MD, PhD,<sup>3</sup> Christopher Li-Hsian Chen, MD.<sup>1,2</sup>

<sup>1</sup>Memory Aging and Cognition Centre, Department of Pharmacology, National University Health System, Singapore

<sup>2</sup>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>3</sup>Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>4</sup>Dementia Collaborative Research Centre – Assessment and Better Care, School of Psychiatry, UNSW Medicine, The University of New South Wales, NSW 2052, Australia

<sup>5</sup>Department of Medicine, National University Health System, Singapore

<sup>6</sup>Neuroscience Clinic, Raffles Hospital, Singapore

<sup>7</sup>Department of Psychology, National University of Singapore, Singapore

#### **CORRESPONDING AUTHOR**

Dr C L-H Chen

Department of Pharmacology

National University Health System

1  
2  
3 Clinical Research Centre, MD11, Level 5, #05-9  
4

5  
6 10 Medical Drive  
7

8  
9 Singapore 117597  
10

11  
12 Phone: +65 65165885  
13

14  
15 Fax: +65 68724101  
16

17  
18 Email: [phccclh@nus.edu.sg](mailto:phccclh@nus.edu.sg)  
19

20  
21 Number of words in abstract: ~~28354~~ words

22  
23 Number of words in manuscripts: ~~2378283~~ words  
24

25  
26 Tables: 3

27  
28 Figures: 0

29  
30 Short title: Neurocognitive status predicts functional outcome after stroke

31  
32 Key Words: Stroke, Predictive value of tests, Cognition, NIHSS, Functional outcome  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** To investigate the prognostic value of the neurocognitive status measured by screening instruments, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), individually and in combination with the stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), obtained at the subacute stroke phase or the baseline ( $\leq 2$  weeks), for functional outcome 3–6 months later.

**Design:** Prospective observational study.

**Setting:** Tertiary stroke neurology service.

**Participants:** 400 patients with a recent ischemic stroke or transient ischemic attack (TIA) received NIHSS, MoCA and MMSE at baseline and were followed up at 3–6 months later.

**Primary outcome measures:** At 3–6 months following index event, functional outcome was measured by the modified Rankin Scale (mRS) scores.

**Results:** Most patients (79.8%) had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median premorbid mRS =0), while a minority of patients had TIA (20.3%). Baseline NIHSS, MMSE and MoCA scores individually predicted mRS scores at 3–6 months, with NIHSS being the strongest predictor (NIHSS:  $R^2$ change=0.043,  $p<0.001$ ). Moreover, baseline MMSE scores had a small but statistically significant incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months, while baseline MoCA scores did not [MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ]. However, in patients with more severe stroke at baseline (defined as NIHSS $>2$ ), both baseline MoCA and MMSE had significant and moderately large incremental predictive value to the baseline NIHSS for mRS scores at 3–6 months [MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  $p=0.021$ ].

1  
2  
3 **Conclusion:** Cognitive screening at the subacute stroke phase can predict functional outcome  
4 independently and improve the predictive value of stroke severity scores for functional  
5 outcome 3–6 months later, particularly in patients with more severe stroke.  
6  
7  
8

## 9 **ARTICLE SUMMARY**

### 10 **Article focus**

- 14 • The prognostic value of neurocognitive status measured by brief screening  
15 instruments, the MoCA and the MMSE, individually and in combination with the  
16 stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), at  
17 subacute stroke phase for functional outcomes at 3–6 months is unknown.  
18  
19 • We examined the predictive ability of MMSE and MoCA individually and in  
20 combination with the NIHSS for functional outcome 3–6 months after mild stroke and  
21 transient ischemic attack.  
22  
23 • We also explored the predictive ability of these measures in patients with differing  
24 stroke severity.  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Key messages**

- 36 • Cognitive screening at the subacute stroke phase can predict functional outcome  
37 independently. Neurocognitive status measured by baseline MMSE scores adds a  
38 small incremental prediction to baseline stroke severity scores for functional  
39 outcomes at 3-6 months in stroke patients.  
40  
41  
42  
43  
44  
45  
46 • Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ ,  
47 neurocognitive status measured by both baseline MMSE and MoCA improve the  
48 predictive value of stroke severity scores for functional outcome 3–6 months later.  
49 However, the incremental predictive value of the MMSE and MoCA is relatively  
50 smaller than the NIHSS.  
51  
52  
53  
54  
55  
56



### Strength and limitations of this study

- The main strength of this study is that we examined the prognostic value of neurocognitive status (MoCA and MMSE) and stroke severity (NIHSS) at subacute stroke phase systematically as a singular measure and in combination for mRS scores 3–6 month later in a large sample of stroke patients and in patients with differing stroke severity.
- An additional strength is the choice of 3–6 month follow-up because patients were more likely to resume their daily activities and usual roles within this time frame. Hence, the findings established in this study can guide early intervention from baseline to 3-6 months after stroke.
- The limitation of this study is that we did not systematically examine rehabilitation services provided for patients from subacute stroke phase to 3-6 months follow-up.

## INTRODUCTION

It is important for early intervention and focused management to have instruments available during the subacute stroke phase for predicting functional outcome 3–6 months later.

Cognitive performance measured by the Montreal Cognitive Assessment (MoCA) and the Mini-mental State Examination (MMSE) administered at the subacute stroke phase predicted patients' functional outcomes at inpatient discharge (1, 2). Furthermore, patients' post-stroke cognitive functioning measured by a brief neuropsychological battery 2–3 weeks following stroke predicted their functional outcomes 13 months later (3). No study yet has investigated the utility of patients' neurocognitive status at the subacute stroke phase for predicting functional outcome at 3–6 months. A widely used stroke severity scale, the National Institute of Health Stroke Scale (NIHSS), administered at the subacute stroke phase is predictive of patients' functional outcomes 3–6 months later (4), but has limited representation of cognitive function (5). Hence, whether the NIHSS and neurocognitive status at baseline are independently predictive or have additive predictive value for functional outcomes at 3–6 months is unknown.

We therefore examined the predictive ability of MMSE and MoCA individually and in combination with the NIHSS at the subacute stroke phase for functional outcome 3–6 months later. In addition, we explored the predictive ability of these measures in patients with differing stroke severity.

## METHODS

### Subjects

The methodology of this study has been described previously (6). [6] Briefly, we recruited 400 consecutive patients ( $\geq 21$  years old) with a recent ischemic stroke or transient ischemic

1  
2  
3 attack (TIA) ( $\leq 14$  days) during their inpatient admission (subacute stroke phase or baseline)  
4  
5 at the National University Health System in Singapore. Patients were excluded if they had a  
6  
7 major physical disability or an active psychiatric disorder that would impede cognitive testing.  
8

### 9 10 **Standard protocol approvals and patient consent**

11 This study was approved by the National Healthcare Group Domain-Specific Review Board  
12  
13 (DSRB), and was conducted in conformity with the Declaration of Helsinki. Written  
14  
15 informed consent was obtained from all participants and/or legally acceptable representatives.  
16  
17

### 18 19 **Procedures**

20 Patients were assessed using the NIHSS, modified Rankin Scale (mRS) (premorbid and  
21  
22 baseline functioning), MMSE (7) and MoCA (8) at baseline. In addition, their mRS scores  
23  
24 were collected at 3–6 months later. The NIHSS and mRS were administered by certified  
25  
26 research personnel blinded to patients' neurocognitive status at baseline and 3-6 months  
27  
28 follow-up. Similarly, the cognitive screening tests were administered by trained research  
29  
30 psychologists blinded to patients' NIHSS and mRS scores. The patients' functional outcome  
31  
32 was defined by the continuous scores of mRS.  
33  
34

### 35 36 37 **Statistical analyses**

38 Between-group differences were examined using independent-sample *t* test for quantitative  
39  
40 variables and Pearson's  $\chi^2$  test for categorical variables. Hierarchical regression analyses  
41  
42 were conducted to examine the incremental contribution of baseline MMSE and MoCA  
43  
44 compared with the baseline NIHSS in predicting functional outcomes defined by mRS scores  
45  
46 at 3–6 months after stroke. In the initial analysis, the clinically-relevant or significant  
47  
48 covariates (i.e., age, sex, years of education, number of cardiovascular risk factors, premorbid  
49  
50 and baseline mRS) were entered in the first block. The cognitive screening variables (MMSE  
51  
52 or MoCA) at baseline were entered in the second block and the NIHSS scores at baseline  
53  
54  
55

1  
2  
3 were entered in the third block (Model A1 and B1 for MMSE and MoCA, respectively).  
4  
5 Subsequently, the order of entry was altered, with baseline NIHSS scores entered in the  
6  
7 second block and either baseline MMSE or MoCA entered at the third block (Model A2 and  
8  
9 B2 for MMSE and MoCA, respectively). In order to explore predictive value in patients with  
10  
11 differing stroke severity, we dichotomized the baseline NIHSS scores using a median split  
12  
13 and repeated these analyses.  
14

15  
16 All statistical analyses were performed with IBM SPSS Statistics Version 20.0 for  
17  
18 Windows.  
19

## 20 21 22 23 **RESULTS**

### 24 25 **Subject characteristics**

26  
27 The recruited patients were mostly Chinese (70.3%) and male (69.8%), with a mean age of  
28  
29 59.8 (11.6) years and a mean of 7.7 (4.3) years of formal education. Most patients (79.8%)  
30  
31 had a mild ischemic stroke and less disability (median NIHSS =2, median mRS =2, median  
32  
33 premorbid mRS =0), while a minority of patients had TIA (20.3%). The median interval  
34  
35 between the stroke or TIA event and assessment was 2 days (range: 0–14).  
36  
37

38  
39 At 3–6 months following the index event, patients who were lost to follow-up ( $n=12$ )  
40  
41 were younger and their clinical condition was stabilized faster than those who completed the  
42  
43 follow-up (age:  $52.8\pm 12.9$  vs  $60.0\pm 11.5$ ,  $p=0.03$ ; interval days:  $2.91\pm 2.31$  vs  $2.08\pm 0.90$ ,  
44  
45  $p=0.01$ ). We defined favorable functional outcome as mRS score  $\leq 1$  and poor functional  
46  
47 outcome as mRS score  $\geq 2$ . This dichotomized mRS scores for favorable and poor functional  
48  
49 outcome is commonly used and is in keeping with the recommendation from previous  
50  
51 analyses (9). The majority of the patients ( $n=252$ , 64.9%) had good functional outcomes  
52  
53 (mRSscore  $\leq 1$ ) while approximately one third of the patients ( $n=136$ , 35.1%) had poor  
54  
55

1  
2  
3 functional outcomes (mRS score  $\geq 2$ ). Patients with poor functional outcome were  
4  
5 significantly older, women, of Malay ethnicity, less educated, more neurologically impaired  
6  
7 with poorer premorbid and baseline functioning, and assessed later following cerebrovascular  
8  
9 event. They also had more stroke classification of large artery occlusion and cardioembolic  
10  
11 stroke, as well as higher number of cardiovascular risk factors. In addition, patients with  
12  
13 poorer functional outcome had significantly lower scores of the MMSE and the MoCA. The  
14  
15 population characteristics of patients with favorable and poor functional outcomes can be  
16  
17 found in Table 1.  
18  
19

### 20 **The Predictive Ability of the MoCA, MMSE and NIHSS**

21  
22 Using hierarchical regression analyses and controlling for baseline characteristics, the MMSE,  
23  
24 MoCA and NIHSS—as singular measures—predicted mRS scores at 3–6 months after stroke  
25  
26 ( $R^2$  changes of 0.012, 0.007 and 0.043, with  $p$ -values 0.004, 0.029 and  $<0.001$ , respectively;  
27  
28 Table 2). Baseline MMSE scores added a small but statistically significant prediction of  
29  
30 functional outcomes in addition to baseline NIHSS scores, while baseline MoCA scores did  
31  
32 not (MMSE:  $R^2$ changes=0.006,  $p=0.03$ ; MoCA:  $R^2$ changes= 0.004,  $p=0.083$ ).  
33  
34  
35

36 Using a median split of baseline NIHSS scores at 2, patients with NIHSS scores  $\leq 2$   
37  
38 (median =1, range 0–2) were defined as having less severe stroke and those with NIHSS  
39  
40 score  $>2$  (median = 5, range 3–18) were defined as having more severe stroke. As shown in  
41  
42 Table 3, in patients with NIHSS score  $>2$ , both baseline MMSE and MoCA had a significant  
43  
44 and considerable incremental prediction for functional outcomes at 3-6 months in addition to  
45  
46 baseline NIHSS scores (MMSE:  $R^2$ changes=0.021,  $p=0.010$ ; MoCA:  $R^2$ changes=0.017,  
47  
48  $p=0.021$ ), while neither baseline neurocognitive measure nor baseline NIHSS showed an  
49  
50 incremental prediction for functional outcome in patients with less severe stroke (NIHSS  
51  
52 score  $\leq 2$ ).  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Cognitive screening at the subacute stroke phase can predict functional outcome at early convalescent stroke phase independently. Baseline MMSE scores add a small incremental prediction to baseline stroke severity scores for functional outcomes at 3-6 months in stroke patients. Additionally, in patients with more severe stroke defined by baseline NIHSS score  $\geq 2$ , both baseline MMSE and MoCA improve the predictive value of stroke severity scores for functional outcome 3–6 months later. However, the incremental predictive value of the MMSE and MoCA is relatively smaller than the NIHSS.

The contributions of our study are three-fold. First, our finding that neurocognitive status at the subacute stroke phase predicts functional outcome at 3–6 months is novel and consistent with previous studies in inpatient rehabilitation (1, 2) and at 13 months after stroke (3). Second, MMSE scores at baseline add a small incremental prediction to baseline stroke severity scores for functional outcomes 3-6 months later. Third, both baseline MMSE and MoCA showed a considerable incremental effect to the baseline NIHSS scores in predicting functional outcomes in patients with more severe stroke (NIHSS $>2$ ) while neither neurocognitive measure nor stroke severity score at baseline was predictive for functional outcome in patients with less severe stroke (NIHSS score  $\leq 2$ ). This may be explained by the higher recovery potential of patients with more neurological deficits compared to patients with less severe deficits.

There are several strengths of our study. First, we examined the prognostic value of NIHSS and cognitive status by systematically assessing baseline values individually and in combination in predicting patients' mRS scores 3–6 month after stroke. Although previous studies that investigated the predictive power of cognition included baseline NIHSS as a control variable (along with other baseline characteristics), they did not explore the role of

1  
2  
3 baseline NIHSS as a predictor itself (1-3). Second, we chose the 3–6 month follow-up period  
4  
5 because prognosis of functional recovery can be made reliably within 12 weeks after stroke  
6  
7 (10), and patients were more likely to resume their daily activities and usual roles within this  
8  
9 time frame. Therefore, the findings established in this study can guide early intervention from  
10  
11 baseline to 3-6 months after stroke. Third, we examined the predictive ability of  
12  
13 neurocognitive status and stroke severity measures at baseline for functional outcome at 3-6  
14  
15 months in patients with differing stroke severity.  
16  
17

18  
19 There are several limitations of this study. First, our results may not be generalizable  
20  
21 as the majority of patients had less severe stroke, nevertheless, a third had poor functional  
22  
23 outcomes 3–6 months after stroke so better prognostic tools are required. Second, we  
24  
25 employed cognitive screening tests at baseline rather than formal neuropsychological  
26  
27 assessments, for their brevity and utility by non-specialist personnel. Third, we did not  
28  
29 examine rehabilitation services systematically as this information was not collected.  
30  
31 However, all patients received standard rehabilitation according to the institutional pathway.  
32  
33 Fourth, the mRS has been criticized for its lack of specificity (5), however, it is a summary of  
34  
35 outcomes in functioning and has been widely used in clinical trials as a primary efficacy  
36  
37 measure. Last, we did not consider other predictive scores (e.g., PLAN score (11), iScore (12),  
38  
39 six simple variable (13) and five simple variable scores (14)) for our models primarily due to  
40  
41 the following reasons: 1) None of these scores include a cognitive measure.; 2) PLAN scores  
42  
43 are developed using more severe functional outcome measure, such as mRS scores of 5 to 6  
44  
45 at discharge. Similarly, iScore has been used to estimate poor functional outcome defined by  
46  
47 mRS 3 to 5. ; 3) Six simple variable and five simple variable scores require Glasgow Coma  
48  
49 Scale which we did not collect in this study. Therefore, we are unable to adopt these models  
50  
51 to predict functional outcome in this study. However, in line with our aims, we included  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 significant and clinically relevant predictors as control variables (age, sex, education,  
4  
5 composite of cardiovascular risk factors, premorbid mRS and baseline mRS) in our models.  
6

7 Our prediction models can be applied to patients with mild ischemic stroke and TIA,  
8  
9 especially in those with NIHSS score >2. The routine cognitive screening at subacute stroke  
10 phase with either MoCA or MMSE could add incremental predictive value to the NIHSS of  
11 patients with NIHSS score >2 for functional outcomes at 3-6 months. However, this model  
12 has yet to be validated externally, therefore it may not be generalizable to other stroke  
13 population.  
14  
15  
16  
17  
18  
19

20  
21 In conclusion, 4.3% of the functional outcome after 3-6 months can be predicted early  
22 after admission by NIHSS, with its many functional and only few cognitive items. Premorbid  
23 and baseline factors alone however, explain almost half of the variance. In addition,  
24  
25 neurocognitive status at the subacute stroke phase is independently predictive of functioning  
26  
27 at early convalescent stroke phase. Baseline MMSE scores can add incremental prediction to  
28  
29 baseline stroke severity score for functional outcome 3-6 months later. Moreover, in patients  
30  
31 with more recovery potential, both baseline MMSE and MoCA can improve baseline stroke  
32  
33 severity score in predicting functional outcomes 3–6 months later. We have previously shown  
34  
35 that these screening tests administered at the subacute stroke phase could also predict  
36  
37 cognitive outcomes 3–6 months later (6). In addition, MoCA administration has been reported  
38  
39 to be applicable to the majority of acute stroke patients (ischemic or hemorrhagic)  
40  
41 (82.5%), and therefore feasible to be used in acute stroke phase (15). Therefore, the predictive  
42  
43 value and brevity of the MMSE and MoCA warrants their routine use in the subacute stroke  
44  
45 phase in clinical service and early acute stroke trials. However, the current instruments  
46  
47 (NIHSS in combination with MMSE or MoCA) could only predict for 51% of the functional  
48  
49 outcome. Therefore, it would be helpful if a better prognostic tool can improve the prediction  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 for functional outcome to 70%-80%. Future studies may establish a modified scale  
4  
5 combining the NIHSS and items from the MMSE and MoCA to improve the predictive  
6  
7 ability for functional outcome.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Population characteristics according to the functional outcome defined by mRS scores at 3-6 months after stroke

Characteristics N (%)	mRS 0–1		mRS ≥2		Univariate Analysis
	(n = 252)		(n = 136)		P
Age, mean (SD)	57.9	(10.8)	63.8	(11.8)	<0.001
Gender, female	68	(27.0%)	52	(38.2%)	0.02
Education, y (mean, SD)	9.8	(4.3)	6.3	(3.7)	<0.001
Ethnicity					0.039
<i>Chinese</i>	188	(74.6%)	87	(64.0%)	
<i>Malay</i>	40	(15.9%)	36	(26.5%)	
<i>Indian and others</i>	24	(9.5%)	13	(9.6%)	
Stroke classification					<0.001
<i>SAO</i>	114	(45.2%)	60	(44.1%)	
<i>LAA</i>	29	(11.5%)	30	(22.1%)	
<i>CE</i>	31	(12.3%)	25	(18.4%)	

Characteristics N (%)	mRS 0–1		mRS ≥2		Univariate Analysis
		(n = 252)		(n = 136)	P
<i>UND and OC</i>	12	(4.8%)	8	(5.9%)	
<i>TIA</i>	66	(26.2%)	13	(9.6%)	
NIHSS ( mean, SD)	1.46	(1.83)	5.04	(3.68)	<0.001
Premorbid mRS (median )	0.06	(0.29)	0.54	(1.05)	<0.001
Baseline mRS (median )	1.28	(1.20)	3.04	(1.21)	<0.001
Mean interval (days) between stroke/TIA and assessment	2.4	(2.0)	3.8	(2.5)	<0.001
Cognitive screening tests					
<i>MMSE (mean, SD)</i>	25.7	(3.3)	22.6	(4.3)	<0.001
<i>MoCA (mean, SD)</i>	22.0	(4.8)	18.1	(5.5)	<0.001
Number of cardiovascular risk factors (median)	2		3		<0.001
Recurrent vascular events (no., %)	10	(4.0%)	8	(6.0%)	0.37

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Characteristics N (%)	mRS 0–1 (n = 252)	mRS ≥2 (n = 136)	Univariate Analysis <i>P</i>
-----------------------	----------------------	---------------------	---------------------------------

**mRS** = modified Rankin scale; **SD**= Standard Deviations; **SAO** = small artery occlusion; **LAA**= large artery atherosclerosis; **CE** = cardioembolism; **UND** = undetermined etiology; **OC** = other determined etiology; **TIA**= transient ischemic attack; **NIHSS** = National Institute of Health Stroke Score; **MMSE**=Mini-Mental State Examination; **MoCA**=Montreal Cognitive Assessment.

For Peer review only

Table 2. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS scores

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	54.10	<0.001
A1	2	Baseline MMSE	−0.1 (0.031)	0.47	0.012	8.48	0.004
	3	Baseline NIHSS	0.3 (<0.001)	0.51	0.038	29.00	<0.001
A2	2	Baseline NIHSS	0.3 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MMSE	−0.1 (0.031)	0.51	0.006	4.71	0.031
B1	2	Baseline MoCA	−0.08 (0.083)	0.47	0.007	4.80	0.029
	3	Baseline NIHSS	0.31 (<0.001)	0.51	0.040	31.10	<0.001
B2	2	Baseline NIHSS	0.31 (<0.001)	0.50	0.043	33.00	<0.001
	3	Baseline MoCA	−0.08 (0.083)	0.51	0.004	3.02	0.083

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

Table 3. Hierarchical regression of mRS scores at 3–6 months after stroke on baseline MMSE, MoCA and NIHSS for subsample of patients with NIHSS scores >2 at baseline

Model	Block	Variables	Final $\beta$ (p)	R <sup>2</sup>	R <sup>2</sup> change	F change	p-value
	1	Controls <sup>a</sup>		0.46	0.460	21.68	<0.001
A1	2	Baseline MMSE	−0.18 (0.010)	0.49	0.036	10.94	0.001
	3	Baseline NIHSS	0.22 (0.001)	0.53	0.034	11.07	0.001
A2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MMSE	−0.18 (0.010)	0.53	0.021	6.83	0.010
B1	2	Baseline MoCA	−0.16 (0.021)	0.49	0.029	8.51	0.004
	3	Baseline NIHSS	0.22 (0.001)	0.52	0.040	12.07	0.001
B2	2	Baseline NIHSS	0.22 (0.001)	0.51	0.049	15.33	<0.001
	3	Baseline MoCA	−0.16 (0.021)	0.52	0.017	5.42	0.021

<sup>a</sup>Block 1 variables for Block 2 and 3 variables in the models (A1, A2, B1, B2) include age, sex, education, composite of cardiovascular risk factors, premorbid mRS and baseline mRS.

MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Score.

1  
2  
3 **Acknowledgments:** The authors thank all participants for their involvement. They also thank  
4  
5 the research team from NUHS Memory Aging and Cognition Centre for data collection and  
6  
7 the NUHS Medical Publications Support Unit for its editorial support.  
8

9  
10 **Contributors:** Y. Dong drafted the original manuscript. Statistical analysis was conducted by  
11  
12 Ms. Y Dong with the guidance from Dr. J Crawford. All authors contributed to one of: study  
13  
14 design, conceptualization, analysis, interpretation of the data, drafting or revision of the  
15  
16 manuscript for intellectual content.  
17

18  
19 **Funding:** This work was supported by a Center Grant from the National Medical Research  
20  
21 Council (NMRC/CG/NUHS/2010). Y. Dong has received research support by a NMRC  
22  
23 fellowship training award.  
24

25  
26 **Competing interests:** None.  
27

28  
29 **Patient consent:** Obtained.  
30

31  
32 **Ethics approval:** National Healthcare Group Domain-Specific Ethics Review Board.  
33

34  
35 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
36

37  
38 **Data sharing statement:** No additional data are available.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Toglia J, Fitzgerald KA, O'Dell MW, *et al.* The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. *Arch Phys Med Rehabil* 2011;**92**:792–8.
- 2 Zwecker M, Levenkrohn S, Fleisig Y, *et al.* Mini-Mental State Examination, Cognitive FIM Instrument, and the Loewenstein Occupational Therapy Cognitive Assessment: relation to functional outcome of stroke patients. *Arch Phys Med Rehabil* 2002;**83**:342–5.
- 3 Wagle J, Farner L, Flekkøy K, *et al.* Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. *Dement Geriatr Cogn Disord* 2011;**31**:379–7.
- 4 Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. *Stroke* 2012;**43**:560–2.
- 5 Kasner SE. Clinical interpretation and use of stroke scales. *Lancet Neurol* 2006;**5**:603–12.
- 6 Dong Y, Venketasubramanian N, Chan BP, *et al.* Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3–6 months after stroke. *J Neurol Neurosurg Psychiatry* 2012;**83**:580–5.
- 7 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;**12**:189–98.
- 8 Nasreddine ZS, Phillips NA, Bédirian V, *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;**53**:695–9.
- 9 Weisscher, N, Vermeulen M, Ross YB, *et al.* What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2? *J Neurol* 2008;**255**:867-874.



- 1  
2  
3 10 Jørgensen HS, Nakayama H, Raaschou HO, *et al.* Outcome and time course of recovery  
4 in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. *Arch Phys*  
5 *Med Rehabil* 1995;**76**:406-12.  
6  
7  
8  
9  
10 11 O'Donnell MJ, Fang J, D'Uva C, *et al.* The PLAN Score: A bedside prediction rule for  
11 death and severe disability following acute ischemic stroke. *Arch Intern Med*  
12 2012;**172**:1548-1556.  
13  
14  
15 12 Saposnik G, Raptis S, Kapral MK, *et al.* The iScore predicts poor functional outcomes  
16 early after hospitalization for an acute ischemic stroke. *Stroke* 2011;**42**:3421-3428.  
17  
18  
19 20 13 Reid JM, Gubitz GJ, Dai D, *et al.* External validation of a six simple variable model of  
21 stroke outcome and verification in hyper-acute stroke. *J Neurol Neurosurg Psychiatry*  
22 2007;**78**:1390-1391.  
23  
24  
25 26 14 Ayis SA, Coker B, Rudd AG, *et al.* Predicting independent survival after stroke: a  
27 European study for the development and validation of a standardised stroke scales and  
28 prediction models of outcome. *J Neurol Neurosurg Psychiatry* 2013;**84**:288-296.  
29  
30  
31 32 15 Pasi M, Salvadori E, Poggesi A, *et al.* Factors predicting the Montreal cognitive  
33 assessment (MoCA) applicability and performances in a stroke unit. *J Neurol*  
34 2013;**260**:1518-1526.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60